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ABSTRACT

The first part of my dissertation focuses on the expression and function of PPARs
in human melanoma. I found that the A375 cells were significantly growth inhibited
in response to PGJ2 and troglitazone treatment. HEMn-LP showed significant
growth inhibition in response to troglitazone. I found that PPARγ and PPARδ
mRNA is present in both the SK-Mel 28 and A375 cells. The relative level of PPARα
mRNA expression is highest in SK-Mel 28 cells, ~3 fold higher relative to both the
normal human melanocytes and A375 cells. PPARγ protein was ~50% higher in
both SK-Mel 28 and A375 cells relative to the HEMn-LP. PPARα protein levels were
highest in the A375 cells. Consistent 80% knockdown of PPARα was achieved
through siRNA treatment; however, there was no change in cellular morphology.
There was also no decrease in expression of a direct PPARα target, MCAD.
Therefore, a reasonable conclusion is that the increased expression of PPARα in
SK-Mel28 cells is not contributing to its in vitro transformed phenotype.
Hypoxia inducible factor 1α, HIF-1α, is a transcription factor that has been
shown to be a master regulator of oxygen homeostasis. A splice variant of HIF-1α,
HIF-1α785, is missing exon 11 from its oxygen dependent degradation domain. This
region encodes the lysine that is critical for enhancing HIF-1α degradation. The role
of HIF-1α in the progression of human melanoma has not been fully elucidated.
Here, I show for the first time that in human melanoma, HIF-1α is expressed
endogenously with no external stimuli under normoxic conditions. In cell lines
derived from RGP, VGP, and metastatic phases of human melanoma progression,
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the relative amounts of HIF-1α and HIF-1α785 mRNA increase as a function of
malignant progression. The expression levels have been verified by qPCR and
western blot. Overexpression of HIF-1α or HIF-1α785 in SbCl2 cells leads to
increased anchorage independent growth, with HIF-1α785 having the greater
impact. In WM9 cells, inhibition of HIF-1α by siRNA significantly inhibits matrigel
invasion and anchorage independent growth in soft agar. These results show that in
human melanoma, HIF-1α and HIF-1α785 seem to function to increase
tumorgenicity.
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REVIEW OF THE LITERATURE – PART I
MELANOMA
Melanoma is the most serious form of skin cancer. Melanoma cells derive from
the skin’s natural defense system to UV light, the melanocyte. Melanocytes absorb UV
light and in response, produce the pigment, melanin. To defeat the stresses of this
unique function, the melanocytes are inherently and naturally resistant to apoptosis
(Soengas and Lowe 2003). Melanoma incidence is increasing at an alarming rate in the
U.S. Melanoma accounts for 4% of all skin cancers, but for 79% of all skin cancerrelated deaths in the United States (Melanoma Research Foundation fact sheet 2006).
Melanoma has several clinical stages. These range from a radial growth phase
(RGP) → vertical growth phase (VGP) → metastatic melanoma (MM). Radial growth
phase cells have the ability to grow without differentiation; however, they are nontumorigenic in patients and animal models (Satyamoorthy et al., 1999). They have
partial growth autonomy (Hussein MR, 2005). After the accumulation of more genetic
changes such as overexpression of oncogenes and loss of certain tumor suppressor
genes, RGP melanoma cells progress to VGP cells. Vertical growth phase cells have
acquired the ability to invade into the dermis (Satyamoorthy et al., 1999). Metastatic
cells not only have the ability to invade but to also travel to distant sites resulting in
secondary tumors (Figure 1). The later stages of the disease are notoriously resistant
to chemo- and radiotherapy. More investigation is needed to determine targets allowing
circumvention of survival mechanisms inherent not only to melanoma cells, but also to
melanocytes (Soengas and Lowe 2003).
1

Figure 1: Diagram showing the progression from normal human melanocytes to
metastatic melanoma. The progression from melanocytic dysplasia to radial growth
phase represents the initial stage of cancer in human melanoma progression. Radial
growth phase cells have very limited anchorage-independent growth capabilities and
little to no invasion capacity. Vertical growth phase cells are able to form tumors in
mice, have increased anchorage-independent growth capabilities and a high level of
invasion. Metastatic melanoma cells have acquired the ability to travel to secondary
sites to form secondary tumors.
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Figure 1: Progression from normal human melanocytes to metastatic melanoma.

3

NUCLEAR RECEPTORS
Nuclear receptors are a superfamily of transcription factors that regulate the
expression of hundreds of important target genes. These genes can be involved in a
variety of processes including cell division, organogenesis, homeostasis, and
reproduction (Wu et al., 2005). This superfamily includes the vitamin D receptors,
thyroid hormone receptors, retinoid receptors, steroid receptors and several orphan
receptors (no endogenous ligand known). Nuclear receptors are ligand activated and
require the sequential recruitment of coactivators to fully induce gene transcription.
Nuclear receptors allow cells to respond to extracellular signals via the binding of their
respective ligands (Friedmann et al., 2005). Nuclear receptors have several conserved
functional domains (Figure 2). Progressing from the N- to the C- terminus are the first
activation function (AF-1) domain, the DNA-binding domain, a hinge region, as well as a
ligand-binding domain that includes the second activation function (AF-2) domain (Wu
et al., 2005). The AF-1 domain, sometimes referred to as the A/B domain, has
transactivation activity. It has highly variable sequences and lengths among nuclear
receptors and is often the origin of multiple splice variants resulting in different isoforms
of the same nuclear receptor. The DNA-binding domain (DBD) is the most highly
conserved region of the nuclear receptors and is responsible for recognizing and
binding the receptor’s cognate DNA response element in the target gene's promoter
region. The DBD is also responsible for nuclear receptor homo- or heterodimerization.
The ligand binding domain (LBD) of nuclear receptors also varies between nuclear
receptors, but the structure of the LBD is common to nearly all of the nuclear receptors.
4

The LBD has 11-13 alpha helices that form a hydrophobic binding pocket to
accommodate the nuclear receptor ligand. The residues at the bottom of the LBD
pocket confer specificity, determining whether or not the nuclear receptor will bind its
specific ligands such as all-trans retinoic acid, vitamin D3, estrogen, etc. The LBD also
accommodates binding of the nuclear receptor to heat shock proteins as well as
coactivators or corepressors and is also responsible for nuclear localization of the
receptor. The second activation function (AF-2 domain) at the C-terminal end of the
nuclear receptor is thought to act as a "flap" that closes back onto the LBD inducing a
conformational change inhibiting further ligand binding and allowing interaction with
coactivators (McAdara J., 2000).

PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS
Peroxisome Proliferator Activated Receptors (PPARs) are ligand-activated
nuclear receptors. They belong to the subfamily of nuclear receptors termed orphan
receptors. They were first shown to be responsive to a class of chemicals called
peroxisome proliferators. Peroxisomes are cellular organelles that are involved in the
removal of molecular O2 and the breakdown of H2O2. Other functions of peroxisomes
include fatty acid oxidation, cholesterol biosynthesis, and glycerolipid synthesis
(Vamecq et al., 1999). Peroxisome proliferators were shown to cause an expansion of
the population of peroxisomes in the livers of rats (Issemann and Green 1990). The
PPARs have been shown to regulate a myriad of target genes involved in several
biological processes such as inflammation and the immune response, cell proliferation,
cell differentiation, angiogenesis, and lipid and glucose metabolism (Friedmann et al.,
2005).
5

There are 3 isotypes of PPAR: PPARγ, PPARα, and PPARβ/δ. Each isotype is
encoded by a different gene, and has specific functions as well as specific patterns of
tissue distribution. PPARs have been localized mainly to the liver where there is a high
fatty acid metabolism, but have also been reported to be expressed in heart, B and T
lymphocytes (Jones et al., 2002), fat, kidney, vascular smooth muscle and in
keratinocytes (Westergaard et al., 2001). PPARs have the typical nuclear receptor
functional domains; however, each isotype has a distinctive ligand binding domain.
PPAR ligand binding induces conformational changes which stabilize their interaction
with coactivators and destabilize their interactions with corepressors. The three PPARs
have ligand binding domains that are significantly larger than that of other ligandactivated nuclear receptors. The length of the ligand binding domain of the PPARs is
~1300 Å. Of this 1300 Å, only 30-40% is occupied by ligand (Xu et al., 2001). It is
thought that the large size of the ligand binding domain explains why the PPARs can
bind to multiple natural and synthetic ligands. Even though promiscuous, there still
remain structural determinants of each PPAR isotype in their respective ligand binding
domains.
The ligand binding domain of the PPARs also facilitates their heterodimerization
with the receptor for 9-cis retinoic acid, retinoid X receptor (RXR). Once ligand is bound
to the PPAR, there is a conformational change that enables this heterodimerization
(Friedmann et al., 2005). This heterodimerization is necessary for the PPARs to
recognize and bind to their DNA response elements within their target genes’ promoter
regions. The PPAR:RXR heterodimer recognizes a Peroxisome Proliferator Response
Element (PPRE) consisting of a direct repeat (DR) of the hexameric sequence
6

AGGTCA with 1 nucleotide between the repeats. The ligand for the RXR is not required
for the transcriptional activation of the PPAR:RXR heterodimer; however if present, it
has been shown to have a synergistic effect in combination with a PPAR ligand
(Kliewer, S.A. 1992). In the absence of ligand, the PPAR:RXR heterodimer is
associated with corepressors which inhibit its ability to activate gene transcription (Wahli
W., 2002).

PPARγ
Peroxisome Proliferator Activated Receptor γ has a molecular weight of ~56kD.
The gene encoding PPARγ is located on human chromosome 3p25. There are two
isoforms, PPARγ1 and PPARγ2, resulting from 4 splice variants of the PPARγ gene.
Splice variants 1, 3, and 4 encode the same PPARγ1 isoform. Splice variant 2 encodes
the PPARγ2 isoform. PPARγ2 has a longer and distinct N-terminus relative to PPARγ1.

Natural Ligands of PPARγ
Essential fatty acids are required in the human diet and can neither be
synthesized nor derived from other fatty acids. There are two families of essential fatty
acids: Omega-3 (ω-3) and Omega-6 (ω-6). These essential fatty acids are modified to
form lipoxins, resolvins, lipid rafts, and the eicosanoid family of oxygenated hydrophobic
molecules.
Most human eicosanoids are derived from arachidonic acid, a metabolite of
linoleic acid. Arachidonic acid can feed into either the 5-lipoxygenase pathway or into
the cyclooxygenase (prostanoid) pathway. The 5-lipoxygenase pathway results in the
7

Figure 2: Structural diagram of nuclear hormone receptor domains. The variable
NH2-terminal region (A/B) consists of the ligand-independent AF-1 transactivation
domain. The highly conserved DNA-binding domain (C) is responsible for response
element recognition and binding. A variable linker region (D) is connected to the
conserved E/F region that contains the ligand-binding domain, the dimerization surface,
and the ligand-dependent AF-2 transactivation domain.
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Figure 2: Structural diagram of nuclear hormone receptor domains.
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formation of the leukotriene family of eicosanoid lipid molecules. The cyclooxygenase
pathway results in the formation of prostaglandin, prostacyclin, and thromboxane lipid
molecules.
PPARγ can be activated by long chain polyunsaturated fatty acids (PUFAs), fatty
acid components of oxidized low density lipoproteins (LDLs), as well as certain
metabolites derived from the cyclooxygenase and lipoxygenase pathways i.e., 15deoxy-D-12,14-prostaglandin J2 (PGJ2) and 15-S-hydroxyeicosatetraenoic Acid (15-SHETE), respectively. PGJ2, a metabolite of the PGD2 branch of the cyclooxygenase
pathway, is thought to be the most potent endogenous ligand for PPARγ (Forman et. al.,
1995). PGJ2 was shown to directly interact with PPARγ in 1995 by Kliewer et.
al.(Kliewer et al., 1995). Leukemia cell lines (HL-60) treated with PGJ2 showed a
significant decrease in cellular proliferation and DNA synthesis (Yamakawa-Karakida et
al., 2002). In lung cancer cell lines, A549, H345, and N417, 72-hour 4 µmol/L PGJ2
treatment was shown to inhibit their growth by 50%, 90%, and 85% respectively (Avis et
al., 2005). However, PGJ2 has also been reported to be non-specific for PPARγ. Cotreatment experiments in macrophages were conducted with a competitive inhibitor (a
thiazolidinedione (TZD) compound, AD-5075) which could bind PPARγ but not induce
any anti-inflammatory effects. When this inhibitor was used at a concentration that
would have all but completely displaced any PGJ2 binding, PGJ2 treatment exhibited the
same anti-inflammatory effects as those seen in control cells lacking the competitive
inhibitor (Thieringer et al., 2000). It was also shown that in PPARγ-deficient
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macrophages, PGJ2 treatment inhibited PMA-induced IL-6 production at similar levels
compared to the PPARγ-wild type macrophages (Moore et al., 2001).
15-S-HETE was shown to activate PPARγ-dependent transcription in PC3
prostate cancer cells as well as in DU-145 cells (Shappell et al., 2001). Also, when
compared to a known synthetic PPARγ agonist, BRL49653 (rosiglitazone), 15-S-HETE
was also able to induce a dose-dependent inhibition of soft-agar colony formation of
PC3 cells (Shappell et al., 2001).
Lysophosphatidic acid (LPA), a lipid mediator which controls mobility,
differentiation, and cellular growth, is another natural ligand of PPARγ. In competitive
binding studies, LPA was able to displace [3H]-rosiglitazone (a synthetic ligand for
PPARγ) from immobilized PPARγ (McIntyre et al., 2003). LPA was also shown to be
able to stimulate a luciferase reporter gene controlled by a PPRE in RAW264.7 cells, a
macrophage-like cell line. Co-transfection with PPARγ enhanced the effect of LPA on
the PPRE reporter gene luciferase activity (McIntyre et al., 2003). LPA has been shown
to induce the atherosclerotic plaque precursor, neointimas. This LPA-induced neointima
production in rat carotid artery tissue was abolished by treatment with the irreversible
PPARγ antagonist, GW9662 (Zhang et al., 2004).

Synthetic Ligands of PPARγ
Synthetic ligands for PPARγ include the thiazolidinedione (TZD) class of antidiabetic drugs, i.e. Rezulin® (troglitazone) as well as some newly discovered nonthiazolidinedione compounds. TZD derivatives include BRL49653 (rosiglitazone),
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pioglitazone, ciglitazone, and englitazone, and troglitazone (Houseknecht et al., 2002;
Lehmann et al., 1995). TZDs, which are used as insulin sensitizers, are high-affinity
ligands for PPARγ. It has been found that the most potent of the synthetic ligands for
PPARγ is rosiglitazone followed by troglitazone, pioglitazone, ciglitazone, and finally
englitazone (Lehmann et al., 1995). Rezulin® has been shown to bind to PPARγ with
very high affinity Kd = 40nM (Spiegelman B., 1998). Rezulin®’s effects on insulin
sensitivity in humans has been shown to be mediated through PPARγ interactions by
Wilson and Cobb in 1996 (Wilson et al., 1996). While Rezulin® was used to treat type 2
diabetes mellitus, it was determined by the FDA in March 2000 that it had toxic effects
on the liver, relative to other thiazolidinedione derivatives rosiglitazone (Avandia®) and
pioglitazone (Actos®) and was subsequently pulled from the market.
RWJ-348260 is a very potent non-TZD synthetic ligand for PPARγ. Using a
PPARγ-Gal4 chimera reporter assay, RWJ-348260 induced PPARγ reporter gene
transcription with similar effectiveness to rosiglitazone (Rybczynski et al., 2004). RWJ348260 was shown to bind to PPARγ with a binding affinity of Kd = 216 ± 99 nM, similar
to that of rosiglitazone, Kd = 242 ± 22 nM. In vivo, this compound is an insulin
sensitizer. It improved glucose tolerance as well as reduced glucose, insulin, and
HbA1c levels in diabetic animals (Rybczynski et al., 2004).
Recently, a new synthetic non-TZD PPARγ agonist has been found. T33,
formerly called T11, is a benzopyran derivative. T33 was shown to be able to activate a
human PPARγ based reporter gene assay with an EC50 value of 19 nmol/L (Hu et al.,
2006). There was a dose dependent reduction in blood glucose levels which was even
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more significant than what rosiglitazone was able to accomplish in ob/ob mice (Hu et al.,
2006). This study also showed that T33 treatment resulted in a marked improvement in
oral glucose tolerance and insulin tolerance in the ob/ob mice.

PPARγ Antagonists
The most extensively studied aspect of PPARγ has certainly been its ability to
treat type II diabetes via the TZD agonists’ ability to enhance insulin sensitivity and
lower blood glucose and lipid levels. However, there are negative side-effects to these
treatments. PPARγ activation can increase adipocyte differentiation and therefore
weight gain in these patients. There are PPARγ modulators that can potentially have
both anti-obesity as well as anti-diabetic effects. These modulators are more often than
not PPARγ antagonists.
There have been a number of PPARγ antagonists synthesized to date including
GW9662, bisphenol-A-diglicidyl ether (BADGE), PD 068235, LG 100641, GW0072
(partial agonist/antagonist), and recently SR-202 [dimethyl α-(dimethoxyphosphinyl)-pchlorobenzyl phosphate]. GW9662 is an irreversible antagonist for PPARγ (Gupta et al.,
2001). The mechanism of GW9662 antagonism is covalent modification of a cysteine
residue (#285) in the LBD of PPARγ (Leesnitzer et al., 2002). GW9662 has been shown
to have a 10-fold more potent binding to PPARγ than to PPARα, and a 600-fold more
potent binding to PPARγ than to PPARδ (Leesnitzer et al., 2002).
Another PPARγ antagonist is BADGE (Yamauchi et al., 2001). BADGE was
shown to inhibit the transactivation of PPARγ by 70% and to significantly decrease the
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expression of PPARγ target genes such as CD36 (Yamauchi et al., 2001).
PD 068235 is a PPARγ specific antagonist shown to cause a dose-dependent
decrease in rosiglitazone-stimulated PPARγ transactivation with an IC50 of 0.82 µM
(Camp et al., 2001). Co-incubation of rosiglitazone with increasing concentrations of PD
068235 resulted in a dose-dependent decrease in the recruitment of the coactivator
SRC-1 to the PPARγ receptor (Camp et al., 2001). A hallmark of TZD-induced PPARγ
activation is the adipocyte differentiation which has been demonstrated in several
preadipocyte cell lines. PD 068235 was able to antagonize rosiglitazone-stimulated
adipocyte differentiation in vitro (Camp et al., 2001).
LG100641 binds to PPARγ and displaces the TZDs from the receptor but does
not activate transcription of its target genes. LG100641 antagonizes TZD-induced
adipocyte differentiation while retaining the ability to stimulate insulin-mediated glucose
uptake in the adipocytes (Mukherjee et al., 2000). It is thought that this antagonism is a
result of LG100641 binding inhibiting the recruitment of the coactivator SRC-1 to the
PPARγ LBD (Mukherjee et al., 2000).
GW0072 is a partial agonist/antagonist for PPARγ (Oberfield et al., 1999).
GW0072 was shown to activate up to 15-20% of rosiglitazone-induced levels of reporter
activity of a PPARγ-Gal4 chimera plasmid. GW0072 was also shown to be able to
displace the corepressor NCoR from the PPARγ LBD, but was unable to adequately
recruit the coactivators SRC-1 or CBP. Even though GW0072 is able to partially induce
PPARγ-Gal4 chimera reporter gene activity, it does not allow PPARγ to induce
adipocyte differentiation in preadipocyte cell lines that were either treated or untreated
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with rosiglitazone; hence it is termed a partial agonist/antagonist specific for PPARγ
(Oberfield et al., 1999).
SR-202 was shown to be a specific antagonist of PPARγ that could have both
antidiabetic as well as antiobesity activity. SR-202 selectively modulated PPARγ
transcriptional activity measured in HeLa cells using a PPRE-based transcriptional
reporter assay (Rieusset et al., 2002). SR-202 is able to block adipocyte differentiation
induced by either TZDs, dexamethasone, insulin, or 3-isobutyl-1-methylxanthine
(IBMX). In vivo, SR-202 has been shown to block PPARγ activity, thus resulting in a
decrease in fat deposits and an increase in insulin sensitivity (Rieusset et al., 2002).

PPARγ is required for development
Inactivation of both alleles of PPARγ has been shown to be embryonic lethal.
PPARγ deficient CB6F1 mouse embryos die in utero at E9.5-E10 (Rosen et al., 2002;
Barak et al., 1999). PPARγ heterozygotes were able to survive, but were shown to have
increased tumor susceptibility when treated with DMBA (7,12dimethylbenz[a]anthracene), a chemical known to be able to induce tumor formation at
various locations in normal animals. DMBA caused increased tumor formation at every
time point between 2-16 weeks in PPARγ heterozygotes compared to PPARγ wild type
animals (Nicol et al., 2004).
The CRE/loxP system was used to determine the effects of a conditional
disruption of PPARγ (Akiyama et al., 2002). The resulting effect was a nearly complete
deletion of the targeted PPARγ exon 2 which led to a loss of full-length PPARγ mRNA
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and protein. There was lower expression of genes encoding lipoprotein lipases as well
as CD36 and LXRα in the PPARγ null macrophages compared to the PPARγ wild type
macrophages (Akiyama et al., 2002). The CRE/loxP system was also used to determine
the effect of the loss of PPARγ in mammary development in mice (Cui et al., 2002). This
loss neither affected mammary development, nor did it lead to increased spontaneous
tumor formation in the mice (Cui et al., 2002).

REGULATION OF PPARγ

Transcriptional level
The human PPARγ gene is comprised of nine exons and covers over 100
kilobases of genomic DNA (Fajas et al., 1997). The PPARγ promoter region contains a
C/EBP site (Saladin et al., 1999). Both C/EBPβ and C/EBPδ have been shown to
activate the transcription of PPARγ (Saladin et al., 1999; Wu et al., 1995).
Another transcriptional regulator of PPARγ is Adipocyte Differentiation and
Determination factor 1, independently cloned also as Sterol Regulatory Element Binding
Protein 1 (ADD-1/SREBP-1). SREBP-2 also has a binding site within the PPARγ
promoter (Fajas et al., 1999). This family of SREBP transcription factors binds to two
E-box sequence elements either within the PPARγ promoter or 5’ to the promoter
sequence (Fajas et al., 1999). It was shown that overexpression of this family of
transcription factors in HepG2 cells significantly increased PPARγ mRNA levels.
TGFβ treatment of Human Aortic Smooth Muscle Cells (HASMC) was shown to
stimulate PPARγ mRNA expression at early time points (30 minutes – 1 hour). This
16

effect was shown to be mediated by the ERK/Egr-1 signaling pathway since both
pharmacological inhibition of the MEK/ERK pathway, as well as overexpression of
NAB2 (a selective repressor of Egr-1) resulted in the abrogation of early induction of
PPARγ mRNA expression upon TGFβ treatment (Fu et al., 2003). However, TGFβ
treatment was shown to have a biphasic effect on PPARγ mRNA expression. After the
initial early increase, at 6 hours – 12 hours, there was a marked inhibition of PPARγ
mRNA expression, and at 24 hours, expression was completely inhibited. This laterepression effect was shown to be mediated by AP1 and Smad3 (Fu et al., 2003).
PPARγ transcriptional inhibitors were discovered utilizing engineered activatorand repressor- zinc finger proteins (ZFPs). These are engineered from the C2H2 family
of ZFPs to bind with high affinity and specificity to any number of DNA sequences
(Desjarlais, J and Berg 1992; Greisman, H and Pabo 1997). By combining a functional
transcription repressor regulatory element from KRAB with a customized DNA binding
domain directed at the endogenous PPARγ chromosomal loci, it was found that the
engineered six-finger ZFP, ZFP55, was able to inhibit the expression of PPARγ mRNA
in the adipogenic mouse 3T3-L1 cell line (Ren et al., 2002).

Post-translational Regulation
PPARγ has been shown to be regulated at the protein level by several
mechanisms including phosphorylation, ubiquitination, and nitration. PPARγ activity can
be down-regulated by phosphorylation of multiple serine residues including serine 82,
serine 84, serine 110, and serine 112.
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Serine 82 phosphorylation of PPARγ by JNK was shown to negatively regulate
PPARγ activity in vitro in 293T cells (Camp et al., 1999). When Ser82 was mutated to
Ala, the MAPK-induced phosphorylation of PPARγ was abolished in 293T cells (Camp
et al., 1999). EGF treatment, in vivo, resulted in phosphorylation at Ser82 leading to a
reduction in PPARγ transcriptional activity (Camp et al., 1999). Serine 84 was shown to
be phosphorylated by ERK2 and JNK leading to the repression of PPARγ transcriptional
activity in JEG-3 cells (Adams et al., 1997). Serine 110 was shown to be
phosphorylated by MAPK in adipocytes, again resulting in an inhibition of PPARγ
transcriptional activity (Hu et al., 1996). Serine 112 is phosphorylated by ERK (Shao et
al., 1998). A constitutively active PPARγ mutant was produced by mutating the Ser112
to Asp resulting in a decrease in ligand binding as well as coactivator recruitment (Shao
et al., 1998). Phosphorylation of Ser112 is thought to be important in regulating the
conformation of the unliganded receptor, thus altering the ability of PPARγ to bind ligand
efficiently.
In addition to phosphorylation, PPARγ has been shown to be modified at the
post-translational level by ubiquitination which ultimately leads to its degradation via the
proteasomal pathway (Hauser et al., 2000). Ligand activation of PPARγ was shown to
enhance its ubiquitination (Hauser et al., 2000).
Nitration is another post-translational modification of PPARγ. Several tyrosine
residues in PPARγ were shown to be nitrated in response to TNFα, lipopolysaccharide
or peroxynitrite treatment in RAW 264 macrophages (Shibuya et al., 2002). This
nitration was shown to inhibit the ligand-induced translocation of PPARγ from the
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cytosol to the nucleus, thus inhibiting its transactivation potential.

Corepressors and Coactivators
PPARγ has been shown to interact with several coactivators and corepressors
such as Nuclear Receptor CoRepressor (NCoR), CREB binding protein (CBP), p300,
Steroid Receptor Coactivator-1 (SRC-1), and Fatty Acid Binding Protein (FABP).
NCoR is the major corepressor for PPARγ transactivation (Lavinsky et al., 1998).
NCoR was shown to interact with the hinge region of PPARγ (Zamir et al., 1997). Along
with NCoR, other corepressors interact with PPARγ. The SRC-1 coactivator binds the
LBD of PPARγ in a ligand-dependent manner (Zhu et al., 1996). The coactivator p300
interacts with the AF-2 region of PPARγ in a ligand-dependent or -independent manner
(Wang et al., 2001). Antibodies directed at SRC-1 inhibited TZD-dependent PPRE
reporter activation in Rat-1 cells (Westin et al., 1998). Another coactivator for PPARγ is
FABP. Both liver FABP and adipose FABP directly interact with PPARγ (Tan et al.,
2002).

Role of PPARγ in Disease
PPARγ is a key regulator of glucose and lipid homeostasis and its physiological
function has mainly been explored in insulin sensitization, adipocyte differentiation,
inflammation, and development of atherosclerosis. PPARγ has also been implicated in
a number of other conditions including cardiac hypertrophy and more recently, in
carcinogenesis.
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Cancer cells exhibit an inability to balance cell proliferation, apoptosis, and
differentiation, which ultimately leads to tumor formation. PPARγ has been suggested
to play a crucial role in each of these aspects of cancer development. Activation of
PPARγ has been shown to either lead to apoptosis, terminal differentiation, or to the
inhibition of cellular proliferation in several cancer cell lines (Wang et al., 2006).
CDKs have been shown to be directly regulated by PPARγ agonists in several
cancer cell lines. Troglitazone treatment was shown to inhibit the growth of MCF-7
breast cancer cells (Yin et al., 2001). The mechanism of action in these cells is thought
to be interference with several proteins that are regulators of pRb phosphorylation such
as cyclin D1. Re-introduction of cyclin D1 after troglitazone treatment partially rescued
these cells from G1 phase cell cycle arrest.
PPARγ also plays a role in regulating apoptosis. PPARγ activation was shown to
increase caspase-3 activity in human malignant astrocytoma cells (Chattopadhyay et
al., 2000). TNF-related apoptosis inducing ligand (TRAIL)-mediated apoptosis was
triggered by treating multiple cell types, including SK-OV-3 and HUVEC cells with
various PPARγ ligands. Activation of PPARγ was shown to reduce the levels of FLICEInhibitory Protein (FLIP), a negative regulator of TRAIL-induced apoptosis, by
increasing its ubiquitination and subsequent degradation (Kim et al., 2002).
Activation of PPARγ induces differentiation of a number of cancer cell lines. In
human primary and human metastatic breast adenocarcinomas, PPARγ activation by
TZD treatment resulted in changes in the cell’s gene expression pattern to one closely
resembling that of a more differentiated state (Mueller et al., 1998). In T24 bladder
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cancer cells, troglitazone was shown to increase the endogenous PPARγ target gene AFABP, Adipocyte – Type Fatty acid Binding Protein (A-FABP), a well known marker of
differentiation in these cells (Guan et al., 1999).
PPARγ has been shown to play a role in angiogenesis. PPARγ knockout mice
die as embryos at ~ E10 in part due to deficient placental vascularization (Barak et al.,
1999). Rosiglitazone-induced PPARγ activation has been shown to decrease vascular
endothelial growth factor (VEGF), the major regulator of angiogenesis, production in
LLC cells (Panigrahy et al., 2002).
While the majority of reports suggest PPARγ to be a tumor suppressor, there are
a number of studies showing that it could have an opposite effect in some cancers.
Multiple in vivo studies have shown that introducing TZDs into mim mice (mutation in
the APC gene) led to a significant increase in both small and large colon
adenocarcinomas (Saez et al., 1998; Lefebvre et al., 1998).
Transgenic mice expressing high levels of PPARγ were mated with transgenic
mice that expressed the mouse mammary tumor virus polyoma middle T and the
offspring were shown to have an increased incidence of breast cancer formation (Saez
et al., 2004).

Role of PPARγ in melanoma
Expression and effect of ligand activation of PPARγ has been studied in human
melanoma. Both WM35, an early stage melanoma, and A375, a metastatic melanoma
cell line, have been reported to express PPARγ mRNA and protein. While one study
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concluded that the growth of A375 cells was inhibited by ciglitazone (Placha et al.,
2003), another showed that the proliferation of A375 cells was unaffected by this
compound (Nunez et al., 2006). Rosiglitazone has been shown to inhibit colony
formation and induce apoptosis in A375 cells. This study also revealed that
rosiglitazone induced differentiation in the A375 cells (Liu et al., 2006).

PPARα
PPARα has a molecular weight of ~52 kD. The gene has six coding exons and is
located on chromosome 22 in humans (Entrez Nucletide Gene). Active PPARα has
been shown to increase lipid catabolism and decrease circulating lipid concentrations
PPARα has also been shown to play some role in glucose metabolism (Knauf et al.,
2006).

Natural Ligands of PPARα
PPARα is known to be activated by fatty acids and their metabolites. It has been
shown that long-chain fatty acids and eicosanoids are more potent ligands for PPARα
than even its strongest synthetic ligand, WY-14643 (Murakami et al., 1999). This study
showed that the fatty acids and eicosanoids were able to directly bind the LBD of
PPARα. Other studies have shown that mono- and polyunsaturated fatty acids at
physiological concentrations can also directly bind PPARα (Kliewer et al., 1997).
Several arachidonic acid metabolites serve as ligands for PPARα. Leukotriene
B4 (LTB4) activates PPARα and is thought to be the natural ligand for PPARα (Gupta et
al., 2001). LTB4 has been shown to bind to PPARα with a Kd in the nanomolar range,
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while 8-(S) HETE has also been reported to be a natural ligand for PPARα (Lin et al.,
1999).

Synthetic ligands for PPARα
The major class of synthetic ligands for PPARα is the fibrate hypolipidemic drugs.
Fibrates are amphipathic carboxylic acids. They are indicated for the treatment of
several metabolic disorders such as high cholesterol. Some examples of fibrates are
bezafibrate, ciprotibrate, gemfibrozil, fenofibrate, and clofibrates.
The major non-fibrate synthetic agonist for PPARα is WY-14643. WY-14643 is a
well known peroxlsome proliferator having effects on DNA replication via PPARα
(Peters et al., 1997). Results show that PPARα null mice, when fed a diet containing
0.1% WY-14643 exhibited no hepatocarcinomas while 100% of PPARα +/+ mice
showed multiple lesions (Peters et al., 1997).
GW7647 has been recently reported to be a very potent and selective PPARα
agonist. It was shown to have ~ 200-fold selectivity for PPARα over both PPARγ and
PPARδ (Brown et al., 2001),

PPARα Antagonists
The major antagonist for PPARα is MK886. Upon treatment with WY-14643,
MK886 treatment inhibited the activation of PPARα by 80% in A549 cells (Kehrer et al.,
2001). MK886 had only minimal effects on PPARδ or PPARγ activity.
Other inhibitors for PPARα include some acyl – CoA esters. Palmitoyl – CoA
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was shown to bind PPARα and compete with WY-14643 for binding to this receptor
(Elholm et al., 2001). Acyl-CoA esters were shown to directly induce PPARα
conformational change and are thought to be the endogenous regulators of PPARα
activity.

PPARα Knockouts
Mice that lack expression of PPARα exhibit no typical peroxisome proliferation in
response to treatment with clofibrate or WY-14643 (Lee et al., 1995). Also, PPARα null
mice challenged with a diet known to induce insulin resistance were protected from this
effect. These mice, however, did show increased fat deposits (Guerre-Millo et al., 2001).

Regulation of PPARα
The promoter region of PPARα has seven SP- 1 binding sites (Gearing et al.,
1994). Coup – TFII and HNF4 share a binding site within the PPARα promoter (PinedaTorra et al., 2002). While overexpression of HNF4 increased PPARα promoter activity,
overexpression of Coup-TFII decreased the activity of the PPARα promoter.
Other negative regulators of PPARα expression are some cytokines, such as
TNF-α and IL-6, and some members of the STAT family of proteins, including STAT5
(Zhou et al., 1999).

Post – translational PPARα control
PPARα undergoes phosphorylation and ubiquitination (Shalev et al., 1996). The
phosphorylation of PPARα can be induced by several mechanisms/factors. Unlike
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PPARγ, where phosphorylation usually means a decrease in activity, phosphorylation
can serve to activate PPARα transcriptional activity.
PPARα is phosphorylated by MAPK, resulting in transcriptional activation in
insulin-treated HepG2 cells (Juge – Aubry et al.,1999). This phosphorylation of serine12
and serine21 is thought to induce a conformational change which could bring about the
dissociation of the corepressors, NCoR or SMRT, thus increasing transcriptional
activation of PPARα. This phosphorylation results in ligand independent activation of
PPARα. Regulation was further enhanced when fibrate ligand was added to the cells
(Judge – Aubry et al., 1999).
p38 MAPK can also phosphorylate PPARα. This phosphorylation serves to
increase the transcriptional activity of PPARα through conformational change, allowing
interactions with the coactivator PGC-1 (Barger et al., 2001).
Stimulation of protein kinase A (PKA) activity has also been shown to activate
PPARα in the absence of ligand via phosphorylation. This activation was mainly
dependent on an intact AF-2 domain. Phosphorylation by PKA was shown to increase
the stability of the PPARα:DNA interaction resulting in increased transcriptional activity
(Lazennec et al., 2000).
Recently, PKCα and PKCβII have been shown to phosphorylate PPARα.
Phosphorylation sites were mapped to serines 179 and 230. PKC phosphorylation acts
as a switch that converts PPARα from a transcriptional activator to a repressor
(Blanquart et al., 2004).
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PPARα is ubiquitinated and subsequently degraded by the proteasome. Ligand
binding was shown to decrease the ubiquitination and extend the half life of PPARα
(Blanquart et al., 2002).

Role of PPARα in disease
PPARα has been reported to play a major role in transcriptional regulation of the
enzymes involved in the β-oxidation of fatty acids (Barger et al., 2001). In cardiac
metabolism, PPARα has been shown to regulate fatty acid uptake and oxidation (Barger
et al., 2001). In contrast to PPARγ, PPARα can not differentiate fibroblasts into
adipocytes (MacDougald OA and Lane 1995). PPARα agonists such as fibrates have
been shown to lower cholesterol levels by increasing lipoprotein lipase expression in
liver and muscle (Schoonjans et al., 1996). The metabolism of the reverse cholesterol
transport vehicle, HDL, is highly dependent on PPARα activity. Fibrate treatment
results in HDL apolipoprotein gene activation leading ultimately to protection from
atherosclerosis (Lefebvre et al., 2006). Active PPARα has been shown to play a role in
inflammation, serving to decrease cytokine activity (Kleemann et al., 2003). Active
PPARα plays a role in human breast cancer cell proliferation. PPARα agonists WY14643 and clofibrate increased the proliferation of both MCF-7 and MDA-MB-231 cells
(Suchanek et al., 2002). Primary rat liver cultures transiently transfected with human
PPARα were shown to have decreased nafenopin-induced apoptosis relative to control
cells (Roberts et al., 1998).
The role of PPARα in human melanoma remains to be determined. One study
showed that WY-14643 had no effect on the growth of A375 human metastatic
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melanoma cells (Nunez et al., 2005). Other investigators determined that fenofibrate
was able to inhibit the migration of both B16F10 mouse melanoma cells and SK-Mel 28
human vertical growth phase melanoma cells. This inhibition of migration was restored
when cells were treated with the PPARα antagonist, MK886 (Grabacka et al., 2006).

PPARδ
PPARδ is the least studied of the three PPAR subtypes. PPARδ has a molecular
weight of ~48kD. In humans, the gene coding for PPARδ is located on chromosome 6.
PPARδ has been shown to have ubiquitous tissue distribution. It has been reported to
be expressed in spleen, brain, macrophages, heart, adipose, muscle, placenta, lung,
and intestine (Fredenrich and Grimaldi 2004). One of the proposed roles of PPARδ is
that it reportedly plays a role in the regulation of fatty acid oxidation (Frendenrich and
Grimaldi 2004). The activation of PPARδ was shown to reverse the main features of
metabolic X syndrome in mice and monkeys. Some of these effects were a dosedependent rise in serum high density lipoprotein cholesterol and lowering the levels of
small-dense low density lipoprotein, fasting insulin and fasting triglycerides (Fredenrich
and Grimaldi 2004).

Natural ligands of PPARδ
PPARδ can be activated by unsaturated or saturated long-chain fatty acids, some
eicosanoids, prostacyclin, and retinoic acid (Amri et al., 1995; Hertz et al., 1996;
Fredenrich and Grimaldi 2004). The triglyceride components of native very low-density
lipoproteins (VLDLs) are also able to activate PPARδ.
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Synthetic ligands of PPARδ
There are several synthetic ligands for PPARγ and PPARα; however, there is
very limited information on specific synthetic agonists for PPARδ. The major synthetic
agonist for PPARδ is GW501516, a very high affinity ligand with a Ki = 1.1 ± 0.1 nM.
GW501516 was administered to a rhesus monkey model of metabolic X syndrome in
which the lipid profile is representative of that seen in similarly afflicted humans. One
hundred nM GW501516 treatment resulted in an increase of cholesterol efflux from
cells. This effect was attributed to increased PPARδ activity leading to increased
transcription of ABCA1, a reverse cholesterol transporter (Oliver Jr. et al., 2001).
Similar treatment also resulted in a decrease in serum levels of small-dense low-density
lipoprotein, fasting insulin, and fasting triglycerides. GW501516 produced a dosedependent lowering of fasting triglycerides, with a 56% decrease at the 3.0 mg/kg dose
(Oliver Jr. et al., 2001).
Another high affinity ligand for PPARδ is GW0742. This agonist has an EC50 of
1.1 nM with a 1000 fold higher selectivity for PPARδ over both PPARα and PPARγ
(Sznaidman et al., 2003). GW0742 stimulation of PPARβ/δ was found to selectively
induce keratinocyte terminal differentiation and inhibit their proliferation in vivo (Kim et
al., 2006).

PPARδ knockouts
The vast majority of PPARδ -/- mouse embryos die at a very early stage due to a
placental defect. The survivors showed a significant reduction in fat mass (Peters et al.,
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2000; Barak et al., 2002).

Regulation of PPARδ

Transcriptional Regulation of PPARδ
The PPARδ promoter contains Tcf-4 binding sites and AP-1 elements (Entrez
Gene). The AP-1 elements may allow regulation of PPARδ transcription by TPA or
TNFα. TPA induction of PPARδ is mediated through the MAPK pathway (Bryan et. al.,
2006).

Role of PPARδ in disease
Due to the role of PPARδ in regulating lipid metabolism, it is thought to play a
role in atherosclerosis. Whether the role of PPARδ in atherosclerosis is antiatherogenic
or proatherogenic remains to be elucidated (Lee et al., 2003). One study found that
PPARδ is a VLDL sensor in macrophages, suggesting it might be involved in the
accumulation of atherosclerotic plaques (Lee et al., 2003). Another report revealed that
the effect on atherosclerosis may depend on whether or not ligand is bound to PPARδ.
The unliganded PPARδ can sequester BCL-6 allowing progression of the inflammatory
response. Liganded PPARδ releases B-cell lymphoma gene 6 (BCL-6), possibly
resulting in decreased atherosclerosis. (Lee et al., 2003).
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REVIEW OF THE LITERATURE

HIF-1
Oxygen is an essential component for cellular viability. O2 is a critical player in
mitochondrial respiration, ultimately resulting in the formation of ATP from glucose. O2
is the final electron acceptor in the chain of metabolic reactions that result in the
conversion of glucose to CO2 and H2O. This aerobic glycolysis generates 32 molecules
of ATP per molecule of glucose, whereas anaerobic glycolysis only generates 2
molecules of ATP per molecule of glucose (Wiesener and Maxwell 2003).
Consistent with the wide range of physiological functions modulated by O2, the
O2 sensing system is equally necessary and widespread. This O2 sensing system was
uncovered with the discovery that red blood cell production is regulated by
erythropoietin secretion (Bachman et al., 1993). Under hypoxic conditions,
erythropoietin expression was found to increase. It was also found that this increase
was regulated by O2 levels in hepatoma cells (Goldberg et al., 1987). The promoter of
the erythropoietin gene was found to have a hypoxia-responsive element (HRE) and
this element was later shown to bind to a heterodimeric transcription factor, hypoxiainducible factor 1 (HIF-1) (Wang and Semenza 1995). It is this transcription factor that
is the master regulator of oxygen homeostasis.
HIF-1 is a heterodimeric protein complex consisting of a ~120kD HIF-1α subunit
and an ~86kD HIF-1β subunit (Semenza G, 2002). HIF-1 is responsible for the
regulation of >60 genes involved in a myriad of cellular functions and physiological
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processes ranging from angiogenesis to glycolysis to cell proliferation and survival
(Semenza G, 2002).

Structure of HIF-1
HIF-1 is the most important factor involved in the cells’ adaptation to hypoxia
(Mazure et al., 2004). For cells to be able to respond to a range of O2 concentrations,
HIF-1 must be very tightly regulated. The structure of the HIF-1 subunits, especially
HIF-1α, is central to this regulation.
There are multiple isoforms of HIF-1α. HIF-1 can be comprised of either HIF1α:HIF-1β, HIF-2α:HIF-1β, or HIF-3α:HIF-1β. HIF-1α is the full length isoform. HIF-2α
is structurally and functionally similar to HIF-1α, however its tissue distribution is much
more limited. HIF-3α lacks the transactivation domain found in the HIF-1α and HIF-2α
subunits. It is thought that the HIF-3α isoform is a negative regulator of hypoxiainducible gene expression by acting as a competitor for the dimerization of HIF-1α/-2α
to HIF-1β (Jang et al., 2005).
Both the HIF-1α and HIF-1β subunits of HIF-1 are basic helix loop helix (bHLH)
and Per Arnt Sim (PAS) domain proteins. bHLH domains are found in specific DNAbinding proteins that act as transcription factors and are usually 60-100 amino acids
long. A DNA-binding basic region is followed by two alpha-helices separated by a
variable loop region. bHLH regions form homo- and heterodimers (Entrez Conserved
Domains http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml). The PAS domain was
named after three proteins that the domain occurs in: Per- period circadian protein,
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Arnt- Ah receptor nuclear translocator protein, Sim- single-minded protein (Entrez
Conserved Domains http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml).
The HIF-1α subunit is the “inducible” half of this heterodimer while HIF-1β is
considered to be constitutively expressed. The HIF-1α subunit is O2 -labile which is
stabilized by divalent cations, iron chelators, and hypoxia (Giaccia et al., 2003).
Currently, it is believed that the HIF-1A gene transcription is not a major point of
regulation for HIF-1. It is thought that in most cell lines, under both hypoxic and
normoxic conditions that the HIF-1A gene transcription is constitutive (Wenger et al.,
1997).

Regulation of HIF-1

Transcriptional regulation
The human HIF-1A gene, which encodes the HIF-1α protein, consists of 15
exons. It is located on chromosome 14 in humans. There is a splice variant of the HIF1A gene, HIF-1A2, which lacks an alternate segment in the 3' coding sequence,
compared to variant 1, that results in a frame shift. The resulting protein, HIF-1α isoform
2, is shorter and also has a distinct C-terminus, relative to isoform 1 (Entrez Gene
http://www.ncbi.nlm.nih.gov/entrez). The HIF-1B gene encoding the HIF-1β protein has
22 exons and is located on human chromosome 1. There are 2 additional splice
variants for HIF-1B. HIF-1B2 lacks several alternate segments, relative to HIF-1B
variant 1, which leads to a frame shift. The resulting protein, HIF-1β isoform 2, is
shorter and has a distinct C-terminus, compared to HIF-1B variant 1. HIF-1B3 is
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missing an alternate in-frame exon in the 5' coding region, compared to HIF-1B variant
1. This exon deletion results in a protein, HIF-1β isoform 3, that is shorter relative to
HIF-1β isoform 1 (Entrez Gene http://www.ncbi.nlm.nih.gov/entrez).
The promoter of HIF-1A belongs to the TATA-less promoter family and has a GC
rich sequence with several Sp1 binding sites. There are also several HREs within the
promoter of HIF-1A which act as HIF-1 cis elements (Iyer et al., 1998). AP-1 and AP-2
elements are also present in the promoter of HIF-1A (Minet et al.,1999). Downstream of
the initiation site there are several putative transcription factor binding sites including cEts-1, NF-КB, and NF-1 indicating that the transcriptional control of HIF-1A may depend
on cis acting elements located both upstream and downstream of the transcription start
site (Minet et al., 1999). Promoter sequence deletion experiments have shown that the
core promoter sequence of HIF-1A is from +1bp to -200bp. The fragment between
+1bp to -105 bp contains several necessary cis acting elements that control the
increase in the transcription of the HIF-1A gene in response to hypoxia. An AP-1
binding site was found between -29bp to -23bp and could act as a stimulator of HIF-1A
transcription since AP-1 is shown to be activated under hypoxic conditions (Rajpurohit
et al., 1996). Within the sequence spanning -105bp to -201bp there are several AP-2
cis acting elements. AP-2 may play some role in the repression of HIF-1A gene
transcription in response to hypoxia since when this region of the promoter was present
in the promoter-expression constructs, there was a decrease in HIF-1A gene expression
down to normoxic levels upon treatment with CoCl2, a hypoxia mimetic (Minet et al.,
1999).
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Post translational regulation of HIF-1α
It is widely held that HIF-1A gene transcription is not necessarily central to the
regulation of HIF-1 activity. The post translational modifications, however, have been
extensively covered and are considered the de facto method of control of HIF-1
transcriptional activation. The structure of the HIF-1α protein contributes to this
complex pattern of post translational regulation.
HIF-1α consists of several regulatory domains (Figure 3). The N-terminal bHLH
and PAS domains are required for both DNA binding and dimerization with HIF-1β
(Mazure et al., 2004). The C-terminal region of HIF-1α contains the domains that are
required for transactivation and degradation. The oxygen-dependent degradation
domain (ODDD) within HIF-1α contains amino acids that are modified by several
mechanisms including hydroxylation, sumoylation, and acetylation in response to O2
tension (Jiang et al., 1997). There are also two independent transcriptional activation
domains within the C-terminal region termed N-TAD and C-TAD. Between the N-TAD
and C-TAD domains there is an inhibitory domain (ID), which includes residues
contributing to the negative regulation of the transactivation domains (Mazure NM
2004). Several residues within the C-terminal half of HIF-1α are phosphorylated under
normoxic and hypoxic conditions by p42/p44 MAPKs resulting in enhanced
transcriptional activity of HIF-1 (Richard et al., 1999). S-Nitrosation is another posttranslational modification of HIF-1α. The S-nitrosation of Cys800 was shown to
increase HIF-1 transactivation by increasing the interaction of HIF-1 with p300
(Yasinska and Sumbayev 2003).
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Some of these post-translational modifications are involved in regulating HIF-1α
protein stability; others are involved in controlling HIF-1α activity directly. These
methods of control will be discussed in further detail.

Control of HIF-1α protein stability by hydroxylation
The conversion of proline into hydroxyproline requires the activity of irondependent enzymes in reactions requiring oxygen, 2-oxoglutarate, and ascorbate. Two
prolines, Pro402 and Pro564, in HIF-1α are hydroxylated by one of three prolyl
hydroxylase enzymes: PHD1, PHD2, or PHD3. The activity of these enzymes is
regulated by cellular O2 concentration (Epstein et al., 2001). Since these enzymes also
require iron as a cofactor, iron-mimics such as CoCl2 can act as hypoxia mimetics
(Mazure et al., 2004). The cellular localization of the PHD enzymes may play some role
in their activity as well since PHD1 is nuclear, PHD2 is primarily cytoplasmic, and PHD3
can be located in either compartment (Metzen et al., 2003). The hydroxylation of
Pro402 and Pro564 serves to target HIF-1α for interaction with the Von Hipple Lindau
(VHL) tumor suppressor. VHL is the recognition component of an E3 ubiquitin ligase
that brings about the polyubiquitination of HIF-1α, ultimately resulting in the HIF-1α
degradation via the proteasome (Maxwell et al., 1999).
In summary, when cellular O2 concentration is normal (~21%) the PHD enzymes
are active and can therefore hydroxylate HIF-1α resulting in a decrease in HIF-1α
protein stability and an increase in its degradation. Under hypoxic conditions (~2% - 5%
O2 concentration) this chain of events should not occur, allowing HIF-1α, i.e. the HIF-1
heterodimer, to turn on the transcription of its target genes.
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Figure 3: Schematic representation of the functional domains of both HIF-1α full length
and HIF-1α785. Upon loss of exon 11 in HIF-1α785, part of the Oxygen Dependent
Degradation Domain (ODDD) is deleted. This missing region contains the important
lysine 532 residue which is acetylated by ARD1 leading to increased stabilization of
HIF-1α interaction with the von Hippel Lindau tumor suppressor. This interaction directs
HIF-1α to the ubiquitin-proteasome pathway for degradation under normoxic conditions.
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Figure 3: Schematic representation of the functional domains of both HIF-1α full
length and HIF-1α 785.
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Control of HIF-1α protein stability by acetylation
Lys532 within exon 11 of the ODDD of HIF-1α, has been shown to be acetylated
by the arrest-defective-1 (ARD1) protein (Jeong et al., 2002). This acetylation of
Lys532 results in a stabilization of the interaction between HIF-1α and VHL. Thus,
ARD1 acetylation of HIF-1α results in the protein becoming less stable and ultimately
increasing its degradation via the ubiquitin-proteasome pathway. Exon 11 is spliced out
of HIF-1α785, leaving exons 10 and 12 to join in frame. This results in a variant of HIF1α that is thought to be more stable under normoxic conditions due to the ARD1 inability
to acetylate this critical Lys532. No Lys532 acetylation leads to a less stable interaction
between VHL and HIF-1α, which is postulated to result in less degradation via the
ubiquitin-proteasome pathway (Chun et al., 2003).

Control of HIF-1α activity by hydroxylation
In addition to proline hydroxylation, HIF-1α has also been shown to undergo
asparaginyl hydroxylation in response to O2 tension. Under normoxic conditions, the
factor inhibiting HIF-1 (FIH1) catalyzes this asparaginyl hydroxylation which serves to
inhibit the interaction of HIF-1α with p300/CBP. This results in decreased HIF-1
transcriptional activity under normoxic conditions (Lando et al., 2002).

Control of HIF-1α by growth factor stimulation
While the previous examples of control for HIF-1α are O2 dependent, there are
O2 independent mechanisms of HIF-1 control as well. An example of O2 independent
HIF-1 control is via growth factors. Hypoxia increases HIF-1α protein expression in all
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cell types. However, growth factors such as insulin, insulin-like growth factor, and
epidermal growth factor, only stimulate HIF-1α expression in a cell-type dependent
manner. This expression is not dependent on the cellular oxygen concentrations.
Growth factors activate PI3K or MAPK pathways, which in turn, increase HIF-1α protein
expression (Fukuda et al., 2002).

Control of HIF-1α activity by phosphorylation
The MAPK p42/p44 is capable of phosphorylating HIF-1α (Richard et al., 1999).
It was shown that HIF-1α is highly phosphorylated in vivo and that this phosphorylation
results in a change in the electrophoretic migration pattern of HIF-1α. HIF-1α induced
by hypoxia migrates at ~104kD to ~116kD. In HeLa cells, when HIF-1α was
immunoprecipitated and then incubated with lambda phosphatase, this resulted in a
shift of 12kD below the control HIF-1α (no lambda phosphatase treatment) resulting in a
sharp band at ~104kD on the gel (Richard et al., 1999). The p42/p44 phosphorylation
of HIF-1α resulted in an increase in HIF-1 transcriptional activity under normoxic
conditions.

Control of HIF-1α activity by sumoylation
HIF-1α can be sumoylated by the sumo E3 ligase, RanBP2, in vitro (Mazure et.
al., 2004). Sumoylation proceeds similarly to ubiquitination; however, it is not thought to
target proteins for degradation. Sumoylation has been shown to regulate protein
localization and in some instances activation of certain transcription factors (Mazure N
et al.,2004). Sumoylation by SUMO-1 has been shown to increase the stability and
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activity of HIF-1α in vitro (Bae et. al., 2004).

Control of HIF-1α activity by heterodimerization
The dimerization of HIF-1α to HIF-1β is required for HIF-1 transcriptional activity.
This dimerization can be inhibited by competitive binding of inhibitory molecules. An
inhibitory PAS (IPAS) molecule competes with HIF-1β for heterodimerization with the
HIF-1α subunit under hypoxic conditions. This IPAS molecule is the third isoform of
HIF-1α, HIF3α (Jang et al., 2005). Ectopic expression of IPAS in Hepa 1c1c7
hepatoma cells was shown to selectively interfere with the induction of genes that are
up-regulated by hypoxia, including VEGF (Makino et al., 2001). Overexpression of
IPAS also resulted in a decrease in tumor growth and tumor vascular density in mice
(Makino et al., 2001).

HIF-1 antagonists
TX-402, a potent hypoxia-selective cytotoxic agent, was shown to reduce the
expression of VEGF and glucose transporter type 3 (GLUT-3) under hypoxic conditions.
The mechanism of TX-402 action in the reduction of the VEGF and GLUT-3 genes
appears to involve direct suppression of HIF-1α mRNA and protein levels (Nagasawa et
al., 2003).
The National Cancer Institute Diversity Set of 2000 compounds was screened for
potential HIF-1α inhibitors. NSC-134754, a semisynthetic analogue of emetine (a
natural alkaloid) and NSC-643735, a structural analog of actinomycin D aglycone, were
both shown to have HIF-1 inhibitory effects. However, NSC-134754 inhibited hypoxia40

induced HIF-1 activity and HIF-1α protein expression. Hypoxia-induced expression of
Glut-1 was also significantly inhibited by NSC-134754. Both compounds were able to
inhibit growth factor-induced HIF-1α protein expression (Chau et al., 2005).
A screen of 15,000 compounds revealed 3 hits for inhibitors of HIF-1 activity,
DJ12, DJ15, and DJ30 (Jones and Harris 2006). None of the compounds were able to
inhibit HIF-1α protein expression; however they did inhibit hypoxia-induced HIF-1α
target gene expression. DJ12 was the only compound that could inhibit these target
genes in multiple cancer cell lines including breast cancer cells, MDA-468 and ZR-75;
melanoma cell line MDA-435; and pVHL mutant-renal cancer cell lines RCCR and 7860 (Jones and Harris 2006). The DJ12 induced inhibition of HIF-1α target genes was
attributed to the inhibition of HIF-1α DNA binding.

Physiological Roles of HIF-1
HIF-1 is operational in all mammalian cell types, while the HIF-1 – VHL – PHD
system is fully conserved from D. melanogaster to C. elegans to H. Sapiens (Wiesener
and Maxwell 2003). The importance of this system is also underscored by the multitude
of physiological processes that HIF-1 can influence. These processes include
erythropoiesis, iron metabolism, cellular glucose transport, glycolysis, angiogenesis,
regulation of vascular tone, signal transduction, and cell survival (Wenger et al., 2002).
While there is in vitro data that suggests the possibility that HIF-1 is involved in several
physiological and pathological processes, current data on the actual role HIF-1 plays in
vivo is somewhat limited. In vivo data is limited to the role of HIF-1 in embryonic
development, erythropoiesis, and cancer.
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Role of HIF-1 in development
In a mouse model, either VHL, HIF-1α, HIF-2α, or HIF-1β knockouts are
embryonic lethal due to interference with vascular network development (Gnarra et al.,
1997; Ryan et al., 1998; Peng et al., 2000; Maltepe et al., 1997). Reports of either
partial knockout or tissue specific knockout of HIF-1α are very few. One study showed
that tissue specific knockout of HIF-1α in chondrocytes resulted in failed growth plate
development (Schipani et al., 2001).

Role of HIF-1 in ischemia
While the actual role that HIF-1 plays in ischemia is difficult to predict, HIF-1
activation has been detected in certain ischemic conditions. In mice with oxygeninduced ischemic retinopathy, HIF-1α levels were shown to be increased in the retina
(Ozaki et al.,1999). Brain ischemia also resulted in increased HIF-1α activity. HIF-1α
and HIF-1β protein levels were also significantly increased after intraperitoneal injection
of CoCl2 (Bergeron et al., 2000). The kidney exhibits an increased potential for
upregulation of HIF-1 transcriptional activity. Renal ischemia-induced upregulation of
HIF-1α has been reported, with the increase in HIF-1α/2α selective with respect to cell
type and kidney zone, correlating with the known O2 profiles in these areas
(Rosenberger et al., 2002). The functional role of this activation is still under
investigation; however, since increased activation of HIF-1 leads to angiogenesis and
hypoxia-induced metabolic adaptation, this adaptive response should prevent excessive
death of kidney cells (Wiesener and Maxwell 2003).
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Role of HIF-1 in cancer
By far, the most extensively studied area of HIF-1 function and regulation at both
the in vitro and in vivo levels is in cancer biology. HIF-1 activation compensates for an
inadequate O2 supply. Solid tumors have regions of severe hypoxia, especially toward
their core. Normal mammalian cells have evolved very sophisticated mechanisms of
control for HIF-1α. The need for survival under hypoxic conditions for malignant cells
nearly always overpowers this tight control of HIF-1 activity. This survival is
accommodated by increasing HIF-1 activity, which in turn, increases the transcription of
genes involved in angiogenesis and metabolic adaptation. Overexpression of HIF-1α
and HIF-2α has been shown to be poor prognostic indicators for several tumors (Harris
et al., 2002). Monoclonal antibody staining for HIF-1α revealed overexpression in
several cancers including breast, cervix, brain, ovary, oropharynx, and uterus (Semenza
G., 2003). Other reports seemingly show contradictory results for non-small cell lung
cancer and head and neck cancers, revealing that HIF-1α overexpression correlated
with decreased mortality (Beasley et al., 2002; Volm and Koomagi 2000). However,
these results could not be repeated (Giatromanolaki and Harris 2001; Koukourakis et
al., 2002). It seems that while the majority of studies link HIF-1α overexpression and
activity to enhanced tumor progression, the actual effect may be dependent on the type
of cancer as well as the stage of the cancer progression (Semenza G., 2003).
Pancreatic cancer cells, PCI-10, which were overexpressing exogenous HIF-1α
showed a significant increase in the frequency of xenograft growth post injection
(Akakura et al., 2001). This study revealed that transfection of HIF-1α into a series of
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pancreatic cancer cells that were not expressing HIF-1α at high levels made these cells
more resistant to apoptosis and also resulted in increased tumorgenicity.
Hypoxia-induced or exogenous overexpression of HIF-1α directly increased in
vitro invasion by the human colon adenocarcinoma cells, HCT116 (Krishnamachary et
al., 2003). HIF-1α overexpression in tumor xenografts of HCT116 cells resulted in
increased growth and angiogenesis (Ravi et al., 2000).
In addition to overexpression of HIF-1α, the inhibition of this subunit has also
revealed the relevance of HIF-1 to cancer pathology. Inhibition of HIF-1α activity by
overexpression of a dominant-negative form of HIF-1α in pancreatic cancer cells, PCI43, resulted in an increase in apoptotic cells and a decrease in their ability to form
tumors in SCID mice (Chen et al., 2003).
HIF-1α -/- mouse embryonic stem (ES) cells showed significantly impaired
xenograft vascularization compared to HIF-1α +/+ ES cells. HIF-1α null ES cells were
shown to form teratocarcinomas that were only ¼ the size of HIF-1α +/+ ES cells (Ryan
et al., 1998). This study also showed that within the HIF-1α -/- tumors, there was a
significant increase in apoptosis. Transformed fibroblasts derived from the HIF-1α -/mouse embryos exhibited reduced tumor mass at 16 – 18 days post injection (Ryan et
al., 2000).
Inhibition of HIF-2α by siRNA was recently shown to significantly decrease the
growth of neuroblastoma tumor xenografts in athymic mice. HIF-2α was shown to
mediate the chronic response of the cells to hypoxia, while HIF-1α was implicated in the
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acute hypoxia response (Holmquist-Mengelbier et al., 2006).

Role of HIF in melanoma
While there are over 1,000 articles relating to HIF-1 and cancer, there are
relatively few articles discussing HIF-1 activity and its effect on human melanoma. This
is an area of research that is critical, since it is well known that the skin is considered to
have a hypoxic microenvironment. This hypoxic stress is thought to contribute to the
Ras and Akt-induced transformation of normal human melanocytes (Michaylira and
Nakagawa 2006). Akt was only able to transform normal human melanocytes in the
presence of hypoxia (Bedogni et al., 2005). This study also shows that inhibition of HIF1α using siRNA inhibits the Akt-hypoxia induced melanocyte transformation. Inhibition
of HIF-1α expression by rapamycin though mTOR also inhibited melanocyte
transformation (Michaylira and Nakagawa 2006).
A recent study investigated the involvement of HIF-1 in uveal melanoma
migration, invasion and adhesion. It was found that hypoxia increased migration,
invasion and adhesion of Mum2B uveal melanoma cells in vitro. HIF-1α silencing using
RNAi resulted in a significant decrease in uveal melanoma cell migration, invasion and
adhesion (Victor et al., 2006).
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EXPERIMENTAL OBJECTIVE
This project focused on the effect of transcription factors on the progression of
human melanoma. One of the objectives was to elucidate the role of PPARs in cellular
growth and differentiation in human melanoma cell lines SK-Mel 28, A375, and normal
human melanocytes HEMn-LP. The hypothesis was that modulation of the PPARs
activity and/or expression could lead to a less-tumorgenic phenotype in the human
melanoma cells. The first part of this dissertation examined the effects of various PPAR
agonists on these cell lines. Also, I determined the endogenous expression levels of
the PPAR subtypes at both the RNA and protein levels in these cells. The first part of
my dissertation work ends with determining the biological effects of PPARα loss-offunction via siRNA knockdown.
The second part of this dissertation examines the function of HIF-1 in human
melanoma progression. During the course of these experiments, I have found, for the
first time, that the oxygen-labile subunit of HIF-1, HIF-1α, is present under normoxic
conditions in the human metastatic cell lines, A375 and WM9. The hypothesis was that
an increase in expression of HIF1α or HIF-1α785 in radial growth phase cells would
render these cells more tumorgenic while a decrease in the expression of HIF-1α in
metastatic cells would lower their tumorgenicity. I have shown for the first time that
there is regulation of HIF-1α at the mRNA level in human melanoma. qPCR data shows
that HIF-1α mRNA increases as a function of malignant progression while remaining
relatively undetectable in normal human melanocytes. Another objective of the second
half of my dissertation was to determine the biological effects of siRNA-induced HIF-1α

46

loss-of-function in the human metastatic melanoma cells WM9. The last part of my
dissertation work concentrates on the biological effects of HIF-1α gain-of-function in the
radial growth phase human melanoma cell line, SbCl2.
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CHAPTER I

Function of PPARs in human melanoma progression
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INTRODUCTION
Activation of PPARs has been reported to decrease cell growth and stimulate
differentiation in many cancer cell lines. However, there have been very few reports of
the levels of their expression when comparing human melanoma cells to human
melanoctyes. The purpose of the following experiments in the first part of my
dissertation was to characterize the expression and/or function of PPARs in human
melanoma. I found that the levels of PPARγ protein expression were ~50% lower in the
human melanocytes compared to several human melanoma cell lines. PPARα protein
expression was between 80-90% lower in normal human melanocytes than in the
melanoma cell lines, SK-Mel 28 and A375. I also examined the effect of PPAR agonists
on proliferation of the human melanoma cells and normal human melanocytes. I found
that there was a consistent dose dependent decrease in proliferation in the SK-Mel 28,
A375, and the normal human melanocytes upon treatment for 48h with the PPARγ
agonists PGJ2 and troglitazone. Quantigene® mRNA analysis of PPARα revealed
significantly higher levels in human melanoma compared to normal human
melanocytes, correlating to the amount of PPARα protein. PPARα siRNA treatment
consistently decreased PPARα mRNA by ~80%, yet there was no significant change in
morphology, or expression of a PPARα target gene, MCAD. These data suggest that
while PPARα is overexpressed in human melanoma relative to normal human
melanocytes, decreasing its expression has no significant influence on major biological
properties of the melanoma cells.
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MATERIALS AND METHODS

Cell and Culture Conditions
SK-Mel 28 human vertical growth phase melanoma cells were obtained from
American Type Culture Collection (Manassas, VA). They were grown in a humidified
atmosphere of 5% CO2 and 95% air at 37°C in Dulbecco’s Modified Eagle’s Medium
(DMEM). The DMEM contained 1g/L glucose and was supplemented with 10% bovine
calf serum (Gibco, Carlsbad, CA), 50U/mL penicillin G and 50ug/mL streptomycin
sulfate. A375 human metastatic amelanotic melanoma cells were also obtained from
the ATCC. A375 cells were cultured similarly to the SK-Mel 28, with the exception that
10% fetal bovine serum was used as the supplement (Gibco, Carlsbad, CA). Normal
human melanocytes, HEMn-LP (Cascade Biologics, Portland, OR) were grown in 5%
CO2 and 95% air at 37°C. They were grown in Media 254 supplemented with 50mL
human melanocyte growth serum (HMGS) and 1mL penicillin/streptomycin mix (all from
Cascade Biologics, Portland, OR).

PGJ2, Ciglitazone, Troglitazone, WY-14643, and LTB4
PGJ2, ciglitizone, and WY-14643 were obtained from BioMol (Plymouth Meeting,
PA) and were dissolved in DMSO to a stock concentration of 10mM. Fresh dilutions of
each were prepared for each experiment by dilution of the 10mM stock solutions, which
were stored at -20ºC, with tissue culture media prior to cell treatment. Equal volumes of
DMSO were used in the control treated cells. Troglitazone was obtained from Cayman
Chemicals (Ann Arbor, MI) and prepared similarly to the aforementioned compounds.
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LTB4 was purchased from BioMol and was dissolved in 100% ethanol to a stock
concentration of 10nM and stored under a layer of nitrogen gas. LTB4 treatment was
carried out under zero light conditions and the treated cells were protected from light
until assays were performed. Fresh sample was prepared for each experiment and any
remaining solution was discarded. Equal volumes of ethanol were used to treat the
control cells. Forty eight hours after the cells were treated with either of these reagents
they were assayed as described below.

Anchorage-Dependent Growth
All cells were seeded at 5.0 x 105 into 100mm culture dishes. After 72h, cells
were treated with or without various PPAR agonists for 48h. Anchorage-dependent
growth was determined by either hemacytometric analysis or by crystal violet staining.
Hemacytometric analysis was carried out as follows: media was aspirated from the
plates and they were then washed using PBS. After PBS aspiration, cells were
trypsinized for 2 minutes, washed off the plate using the trypsin, pipetted into a 50mL
centrifuge tube, and brought up in 15mL DMEM + 10% BCS. Cells were counted suing
a hemocytometer and corrected for control cell number. Results are expressed as %
control in millions of cells. Experiments are representative of 3 or more independent
assays. Crystal violet staining was performed as follows: Media was aspirated from the
dishes and cells were fixed with 80% methanol for 1h. Next, cells were stained using
0.5% crystal violet for 1h with shaking. After staining, excess crystal violet was
removed from the dishes by extensive washing with distilled H2O. Once excess stain
was removed, stain was eluted from each dish using 1mL of 10% acetic acid and 250µL
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of the eluate was read on the spectrophotometer at 570nm. Results are expressed as
% control. Experiments are representative of 3 or more independent assays.

Relative Melanin Content
Cells were seeded at 5.0 x 105 cells per 100mm dishes. After 72h of incubation,
cells were treated with or without PPAR agonists. Cells were further incubated for 48h,
washed with cold PBS, and dissolved in 1N KOH and incubated at 80°C for 1h. The
lysate was subsequently centrifuged at 12,000 x g for 10 min and the relative melanin
concentration of these supernatants was determined by spectrophotometric analysis at
A462nm and normalized to cell number.
RT-PCR
Total RNA was extracted using Tri-Reagent (Molecular Research Center Inc.,
Cincinnati, OH) as per the manufacturer’s instructions. RNA integrity was determined
using the Agilent Bioanalyzer®. Intact RNA was reverse transcribed to cDNA using the
Advantage RT-for-PCR kit® (Clonetech) as per the manufacturer’s instructions. Five µL
of the resulting cDNA was used in the PCR amplification. PCR amplification was
carried out as described by the manufacturer using the Advantage cDNA kit®
(Clonetech). PPARγ1 forward primer sequences were 5’CCTCGAGGACACCGGAGAG-3’. PPARγ1 reverse primer sequences were 5’CCCTTGCATCCTTCACAAGCATG-3’. PPARγ2 forward primer sequences were 5’GGGTGAAACTCTGGGAGATTCTC-3’. PPARγ2 reverse primer sequences were 5’CCCTTGCATCCTTCACAAGCATG-3’. PPARδ forward primer sequences were 5’-
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ATGGAGCAGCCACAGGAG-3’. PPARδ reverse primer sequences were 5’CCACCAGCTTCCTCTTCTCA-3’. All reactions were carried out for 25-30 pcr cycles.
Typical reaction conditions were 1 min at 94°C; 24-29 cycles at 94°C for 30 sec and
68°C for 4 min; then 5 min at 68°C for the final extension of products. PCR products
were separated by agarose gel electrophoresis using a 1% agarose gel and detected
using ethidium bromide staining. Products were visualized by UV light. Photos were
taken of the gels and visually analyzed for either the presence or absence of a band at
the correct molecular weight.

Quantigene® assay
This method of mRNA analysis was developed by Genospectra, Inc. (now
Panomics Inc.). This assay allows quantitation of mRNA from either whole cell lysate or
extracted total RNA. This assay is based on branched DNA technology. The desired
mRNA is hybridized to a gene specific probe set, here, PPARα. The probe set consists
of three types of probes: Capture Extender, Label Extender, and the Blocking probe, all
designed to hybridize to the target mRNA. Manufacturer supplied protocol was
followed throughout these experiments. Briefly, for the whole cell lysate method:
Lysate from 20,000 cells was loaded in each well of a Quantigene® Capture Plate and
hybridized to probes specific for PPARα mRNA. The ratio of PPARα expression
corrected for β-actin relative to HEMn-LP was calculated. Extracted total RNA method:
2ug/10uL total RNA was loaded in each well of a Quantigene® Capture Plate and
hybridized to probes specific for PPARα mRNA. The fold change of PPARα siRNA
treated cells relative to control siRNA treated cells corrected for B-actin was calculated.
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Western Blotting
Nuclear extract from SK-Mel 28, A375, and HEMn-LP was isolated from each cell
line using the NePER kit® 72 hours after seeding when cells were at ~70% confluence
(Pierce, Rockford, IL) according to the manufacturer’s protocol. For MCAD western blot
analysis, whole cell lysate was isolated from control and siRNA treated SK-Mel 28 cells
at 48h or 96h post treatment. Protein concentration was determined using the BCA
protein assay reagents from Pierce as per the manufacturer’s instructions. 50ug protein
was separated by SDS-PAGE and transferred to nitrocellulose membranes using the
BioRAD MiniProtean3® system. Equal loading was also determined by Ponceau
staining of the nitrocellulose membranes following transfer. Blots were blocked using
ChemiBlocker reagent (Chemicon, Temecula, CA) and probed overnight at 4°C with
either anti-PPARγ monoclonal (Cell Signaling, Danvers, MA) at 1:1000, anti-PPARα
monoclonal (Panomics, Inc., Freemont, CA) at 1:250, or anti-MCAD polyclonal at
1:2000 (Cayman Chemical, Ann Arbor, MI).

Monoclonal mouse secondary IgG

antibody (GE Healthcare, Piscataway, NJ) or polyclonal rabbit secondary IgG antibody
(Cell Signaling, Danvers, MA) was applied after three 1x TBS + 0.05% Tween (TBS-T)
washes. Blots were incubated with secondary antibody at 1:3,000 for 1h at room
temperature and subsequently washed 3x with 1x TBS-T. A final 5 minute wash with
TBS (no Tween) was performed just prior to incubating the blot with ECL reagent for
chemiluminescence detection (GE Healthcare, Piscataway, NJ). Blots were then
autoradiographed and densitometric analysis was performed. For PPAR blots, the ratio
of GAPDH to PPARα or PPARγ is shown.
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siRNA inhibition of PPARα in SK-Mel 28 VGP melanoma cells
SK-Mel 28 cells seeded into 6 well plates at 5.0 x 104 were treated 24h after
seeding with either 100nM PPARα siRNA or 100nM control non-targeting siRNA
(Dharmacon, Inc. Lafayette, CO) using the RNAifect® transfection reagent (Qiagen,
Inc.) as per the manufacturers instructions. Briefly, siRNA oligos were diluted to a stock
concentration of 10mM using 1x siRNA buffer (Dharmacon, Inc. Lafayette, CO). Final
concentration of siRNA (100 nM) was obtained by diluting stock into the appropriate
amount of RNAifect® transfection reagent as per product manual. PPARα inhibition
was confirmed by Quantigene® analysis at 48 and 96h post transfection. There was
~80% decrease in PPARα mRNA relative to PPARα mRNA levels in control siRNA
treated SK-Mel 28 cells at each time point.

Statistical Analysis
Where applicable, data was analyzed by unpaired, two-tailed t tests. Statistical
significance was defined as a p value of 0.05 or less. All error bars shown represent
standard error.
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RESULTS

Anchorage-Dependent growth in human melanoma and normal human
melanocyte cell lines treated with PPAR agonists
The hypothesis that PPARγ or PPARα activation could lead to a less tumorigenic
state in human melanoma was initially tested by determining the effects that various
PPAR agonists had on each of the human melanoma and normal human melanocyte
cell lines. To discern which PPAR subtypes might be involved in anchorage-dependent
growth inhibition, I treated normal human melanocytes, SK-Mel 28 (VGP), and A375
(amelanotic metastatic) human melanoma cells with or without the PPARγ agonists
PGJ2, ciglitazone, or troglitazone. The effects of PPARα activation on anchoragedependent growth were observed by treating these cells with or without the PPARα
agonists WY-14643 or LTB4. Each cell line was treated for 48h and the growth rates
were determined by either hemacytometer or crystal violet staining (Figures 4-16).
Each treatment was performed in triplicate at least 3 times unless otherwise noted.
Contrary to our original hypothesis, the SK-Mel 28 cells were not significantly growth
inhibited by any of the PPARγ or PPARα agonists (Figures 4, 6, 7 and 8). In support of
our hypothesis, however, I found that the A375 metastatic cells were significantly growth
inhibited in response to the natural PPARγ agonist, PGJ2 at 10µM (Figure 9) and the
synthetic PPARγ agonist, troglitazone also at the 10µM concentration (Figure 13).
Troglitazone treatment also resulted in significant anchorage-dependent growth
inhibition in the normal human melanocytes at 10µM (Figure 14). Our hypothesis that
PPARα activation could lead to a significant decrease in anchorage-dependent growth
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in these cells could not be supported by our data. No cell line tested was significantly
affected by any PPARα agonist used. In addition to anchorage-dependent growth,
another marker of cellular differentiation in melanoma is an increase in melanin
production. We hypothesized that treatment of the melanin producing cells with the
PPAR agonists would increase their melanin production, thus indicating a more
differentiated phenotype. However, SK-Mel 28 cells treated with PGJ2 exhibited no
reproducible significant change in melanin production (Figure 5). Normal human
melanocytes had no significant reproducible change in melanin production when they
were treated with the PPARγ agonist troglitazone (Figure 15). A375 cells are
amelanotic, therefore no melanin assay was performed. When treated with PGJ2, the
normal human melanocytes exhibited no significant reproducible change in anchorage
dependent growth (Figure 16).

In support of our hypothesis, I found that anchorage-

dependent growth in the A375 human metastatic melanoma cells and the normal
human melanocytes was significantly affected by PPARγ agonists.

Expression of PPAR subtype mRNA
Since PPAR agonists elicited no significant reproducible effect on anchoragedependent growth in SK-Mel 28 cells, and also in light of the fact that no PPARα agonist
had an effect on any cell line tested, I needed to determine whether or not there was
expression of the PPAR subtypes in the cell lines. To determine the levels of PPARγ1,
PPARγ2, and PPARδ mRNA, RT-PCR was performed in the SK-Mel 28 and A375 cells.
These results show that PPARγ1, PPARγ2, and PPARδ are all expressed in these cell
lines (Figure 17). To determine the relative levels of PPARα in the normal human
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melanocytes, SK-Mel 28, and A375 cells, the Quantigene® assay was used. I found
that PPARα mRNA levels were ~2 fold higher in the SK-Mel 28 cells relative to the
normal human melanoctyes (Figure 18). A375 levels of PPARα mRNA were only ~0.14
fold higher than the levels found in the normal human melanocytes (Figure 18). To
summarize, both SK-Mel 28 and A375 cells were positive for PPARγ1, PPARγ2, PPARδ,
and PPARα mRNA expression. The normal human melanocytes were only tested for
PPARα and were positive for this PPAR subtype mRNA.

58

Figure 4: Anchorage-dependent growth study in SK-Mel 28 treated with PGJ2.
SK-Mel 28 cells (5.0x105) were seeded into each 100mm dish. At 72h post seeding,
cells were treated with or without agonist. The PPARγ agonist, PGJ2, or DMSO vehicle
(Control) was used to treat SK-Mel 28 cells. After 48h treatment, cellular growth was
determined by crystal violet staining as described in materials and methods. Results
are expressed as fraction of control. Experiments were performed in triplicate and
figure is representative of 3 or more independent assays. Error bars represent standard
error.
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Figure 4: Anchorage-dependent growth study in SK-Mel 28 treated with PGJ2
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Figure 5: Melanin production in SK-Mel 28 treated with PGJ2. SK-Mel 28 cells were
seeded at 5.0x105 into 100mm dishes. Seventy two hours later, cells were treated with
PGJ2 or DMSO vehicle (Control) for 48h. Cells were subsequently lysed with 1N KOH
and the lysate was placed in 80ºC water bath. One hundred µL of cellular lysate was
loaded into the wells of a 96-well plate and the amount of melanin determined by
measuring the absorbance at 462 nm. Results are corrected for cell number and shown
as fraction of control.
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Figure 5: Melanin production in SK-Mel 28 treated with PGJ2
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Figure 6: Anchorage-dependent growth study in SK-Mel 28 treated with
ciglitazone. SK-Mel 28 cells were seeded at 5.0x105 cells per 100mm dish. At 72h
post seeding the PPARγ agonist, ciglitazone (Cig) or DMSO vehicle (Control) was used
to treat the cells. After 48h of troglitazone treatment, cellular growth was determined by
hemocytometric analysis. Cells were counted and corrected for control cell number.
Results are expressed as fraction of the control. Experiments were performed in
triplicate and figure is representative of 3 or more independent assays. Error bars
represent standard error.
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Figure 6: Anchorage-dependent growth study in SK-Mel 28 treated with
ciglitazone
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Figure 7: Anchorage-dependent growth study in SK-Mel 28 treated with WY14643. SK-Mel 28 cells were seeded at 5.0x105 cells per 100mm dish. At 72h post
seeding the PPARα agonist, WY-14643 (WY) or DMSO vehicle (Control) was used to
treat the cells. After 48h of WY-14643 treatment, cellular growth was determined by
hemocytometric analysis. Cells were counted and corrected for cell number. Results
are expressed as fraction of control. Experiments were performed in triplicate and
figure is representative of 3 or more independent assays. Error bars represent standard
error.
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Figure 7: Anchorage-dependent growth study in SK-Mel 28 treated with WY14643
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Figure 8: Anchorage-dependent growth study in SK-Mel 28 treated with
troglitazone. SK-Mel 28 cells were seeded 5.0x105 cells per 100mm dish. At 72h post
seeding the PPARγ agonist, troglitazone (Trog), or DMSO vehicle (Control) was used
to treat the cells. After 48h of troglitazone treatment, cellular growth was determined by
crystal violet staining as described in materials and methods. Results are expressed as
fraction of control. Experiments were performed in triplicate and figure is representative
of 3 or more independent assays. Error bars represent standard error.
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Figure 8: Anchorage-dependent growth study in SK-Mel 28 treated with
troglitazone
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Figure 9: Anchorage-dependent growth study in A375 treated with PGJ2. A375
cells were seeded at 5.0x105 cells per 100mm dish. At 72h post seeding, the PPARγ
agonist, PGJ2, or DMSO vehicle (Control) was used to treat the cells. After 48h of
PGJ2 treatment, cellular growth was determined by crystal violet staining as described in
materials and methods. Results are expressed as fraction of control. Experiments were
performed in triplicate and figure is representative of 3 or more independent assays.
Error bars represent standard error. * denotes p < 0.006
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Figure 9: Anchorage-dependent growth study in A375 treated with PGJ2
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Figure 10: Anchorage-dependent growth study in A375 treated with ciglitazone.
A375 cells were seeded at 5.0x105 cells per 100mm dish. At 72h post seeding the
PPARγ agonist, ciglitazone (Cig), or DMSO vehicle (Control) was used to treat the
cells. After 48h of ciglitazone treatment, cellular growth was determined by
hemacytometric analysis. Cells were counted and corrected for DMSO treated (control)
cell number. Results are expressed as fraction of control. Experiments were performed
in triplicate and figure is representative of 3 or more independent assays. Error bars
represent standard error.
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Figure 10: Anchorage-dependent growth study in A375 treated with ciglitazone
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Figure 11: Anchorage-dependent growth study in A375 treated with WY-14643.
A375 cells were seeded at 5.0x105 cells per 100mm dish. At 72h post seeding the
PPARα agonist, WY-14643 (WY), or DMSO vehicle (Control) was used to treat the
cells. After 48h of WY-14643 treatment, cellular growth was determined by
hemacytometric analysis. Cells were counted and corrected for DMSO treated control
cell number. Results are expressed as fraction of control. Experiments were performed
in triplicate and figure is representative of 3 or more independent assays. Error bars
represent standard error.
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Figure 11: Anchorage-dependent growth study in A375 treated with WY-14643
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Figure 12: Anchorage-dependent growth study in A375 treated with LTB4. A375
cells were seeded at 5.0x105 cells per 100mm dish. At 72h post seeding the PPARα
agonist, LTB4, or ethanol vehicle (Control) was used to treat the cells. After 48h of
LTB4 treatment, cellular growth was determined by hemacytometric analysis. Cells
were counted and corrected for DMSO treated control cell number. Results are
expressed as fraction of control. Experiments were performed in triplicate and figure is
representative of 3 or more independent assays. Error bars represent standard error.
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Figure 12: Anchorage-dependent growth study in A375 treated with LTB4.
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Figure 13: Anchorage-dependent growth study in A375 treated with troglitazone.
A375 cells were seeded at 5.0x105 cells per 100mm dish. At 72h post seeding the
PPARγ agonist, troglitazone (Trog), or DMSO vehicle (Control) was used to treat the
cells. After 48h of troglitazone treatment, cellular growth was determined by crystal
violet staining as described in materials and methods. Results are expressed as
fraction of control. Experiments were performed in triplicate and figure is representative
of 3 or more independent assays. Error bars represent standard error. * denotes p <
0.003
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Figure 13: Anchorage-dependent growth study in A375 treated with troglitazone
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Figure 14: Anchorage-dependent growth study in HEMn-LP treated with
troglitazone. HEMn-LP cells were seeded at 5.0x105 cells per 100mm dish. At 72h
post seeding the PPARγ agonist, troglitazone (Trog), or DMSO vehicle (Control) was
used to treat the cells. After 48h of troglitazone treatment, cellular growth was
determined by crystal violet staining as described in materials and methods. Results
are expressed as fraction of control. Experiments were performed in triplicate and
figure is representative of 3 or more independent assays. Error bars represent standard
error. * denotes p < 0.002
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Figure 14: Anchorage-dependent growth study in HEMn-LP treated with
troglitazone
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Figure 15: Melanin production in HEMn-LP treated with troglitazone. HEMn-LP
cells were seeded at 5.0x105 into 100mm dishes. At 72h post-seeding cells were
treated with troglitazone (Trog) or DMSO vehicle (Control) for 48h. Subsequently, cells
were lysed and melanin assay was performed as described in materials and methods.
Results are corrected for cell number and shown as fraction of control. Experiments
were performed in triplicate and figure is representative of 3 or more independent
assays. Error bars represent standard error.
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Figure 15: Melanin production in HEMn-LP treated with troglitazone
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Figure 16: Anchorage-dependent growth study in HEMn-LP treated with PGJ2.
HEMn-LP cells were seeded at 5.0x105 cells per 100mm dish. At 72h post-seeding, the
PPARγ agonist, PGJ2, was used to treat the cells. After 48h of PGJ2 or vehicle (DMSO)
treatment, cellular growth was determined by crystal violet staining as described in
materials and methods. Results are expressed as fraction of DMSO treated (control)
cells. Experiments were performed in triplicate and figure is representative of 3 or more
independent assays. Error bars represent standard error.
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Figure 16: Anchorage-dependent growth study in HEMn-LP treated with PGJ2
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Figure 17: RT-PCR for PPARs in human melanoma cells. Total RNA was extracted
from SK-Mel 28 vertical growth phase cells and A375 metastatic melanoma cells at 72
hours post-seeding when cells were at ~70% confluence. RNA integrity was
determined using the Agilent Bioanalyzer®. RNA was reverse transcribed using the
Advantage RT-for PCR kit®. 5uL of the resulting cDNA was used in the PCR reaction
as described in the Advantage cDNA kit® manual using primers specific for either
PPARγ1, PPARγ2, or PPARδ.
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Figure 17: RT-PCR for PPARs in human melanoma cells

28
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Figure 18: Quantigene® analysis to determine relative expression of PPARα
mRNA. The Quantigene® assay system was used to determine the relative levels of
PPARα mRNA in HEMn-LP, SK-Mel 28, and A375 human melanoma cells. This assay
allows quantitation of mRNA species directly from cell lysates without the need to
isolate total RNA. Cells were harvested at ~70% confluence. Total cell extract from
20,000 cells was loaded in each well of a Quantigene® Capture Plate and hybridized to
probes specific for PPARα mRNA. The data is expressed as the fold increase of
PPARα expression corrected for β-actin expression (internal control) relative to the
amount of HEMn-LP PPARα expression (also corrected for β-actin expression).
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Figure 18: Quantigene® analysis to determine relative expression of PPARα
mRNA
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Expression of PPAR subtype protein
While PPAR subtype mRNA was shown to be present in each cell line tested, the
protein levels had yet to be determined. Relative protein expression levels of PPARα
(Figure 19) and PPARγ (Figure 20) subtypes were determined by western blot
analysis. Either whole cell lysates or nuclear extracts from normal human melanocytes,
SK-Mel 28, or A375 cells were subjected to SDS-PAGE and the resulting blots were
visualized and density of the immunoreactive PPAR protein signals analyzed using the
BioRad Chemi-Doc®. All blots were re-probed with GAPDH antibody and the density of
the PPAR reactive protein signal divided by the density of the GAPDH signal. I found
that PPARα protein levels were highest in the A375 cells (Figure 19). PPARγ protein
was ~50% higher in both SK-Mel 28 and A375 melanoma cells relative to the normal
human melanocytes (Figure 20). SK-Mel 28 PPARα protein was ~20% less than that
of A375 cells while the normal human melanocytes had ~70% less than the A375 cells
(Figure 19).

Decrease in SK-Mel 28 cell PPARα by siRNA knockdown
Since the mRNA levels of PPARα were highest in the SK-Mel 28 cells, siRNA
targeting PPARα was used to determine the effects of PPARα knockdown on the
physiology of these human melanoma cells. Even though consistent 80% PPARα
mRNA knockdown was achieved (Figure 21), as determined by the Quantigene®
assay, no major biological effect was seen in these cells. There was no change in
morphology in these cells treated with PPARα siRNA compared to control siRNAtreated cells (Figure 23 A and B). The expression of MCAD is a direct indicator of
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PPARα transcriptional activity. The expression of MCAD should decrease when the
PPARα level/activity decreases. This was not the case as shown in Figure 22.
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Figures 19: PPARα protein expression in human melanoma and normal
melanocytes. Fifty µg nuclear extract from SK-Mel 28, A375, and HEMn-LP was
separated by SDS-PAGE. The resulting blot was probed with PPARα antibody
(Panomics, Inc.) at a titer of 1:250 and bands were visualized by chemiluminescence.
Densitometry was performed and the ratio of PPARα to GAPDH relative to SK-Mel 28
was calculated. Data is shown as fraction of control (SK-Mel 28). M = molecular weight
marker.

91

Figure 19: PPARα protein expression in human melanoma and normal
melanocyte
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Figure 20: PPARγ protein expression in human melanoma and HEMn-LP. Fifty µg
whole cell lysate was extracted from SK-Mel 28, A375, and HEMn-LP and subsequently
separated by SDS-PAGE. The resulting blot was probed using Anti-PPARγ (Cell
Signaling, Inc.) at 1:1000. Bands were visualized using chemiluminescence detection.
Densitometric analysis was performed and the ratio of PPARγ to GAPDH relative to SKMel 28 was calculated. Data is presented as fraction of control (SK-Mel 28). Data is
presented fold change.
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Figure 20: PPARγ protein expression in human melanoma and HEMn-LP
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Figure 21: Quantigene® analysis to determine siRNA knockdown of PPARα. SKMel 28 cells were seeded at 1.5x105 cells/well into a 6-well plate. At 24 hours postseeding, cells were treated with 100nM PPARα siRNA using the RNAifect® kit (Qiagen,
Inc). Total cellular RNA was isolated 48h or 96h later, using Tri Reagent® (Molecular
Research Corp. Cincinnati, OH). RNA integrity was determined using the Agilent
Bioanalyzer®. The Quantigene® assay system was used to determine % knockdown of
the PPARα mRNA. The Quantigene® assay is based on branched DNA technology
that allows quantitation of mRNA species from total RNA. The desired mRNA is
hybridized to a gene specific probe set, here, PPARα. The probe set consists of three
types of probes: Capture Extender, Label Extender, and the Blocking probe, all
designed to hybridize to the target mRNA. Total RNA (2 µg/10µL) was loaded in each
well of a Quantigene® Capture Plate and hybridized to probes specific for PPARα
mRNA. The ratio of PPARα to β-actin (internal control) was calculated. The data is
presented as a fraction of control siRNA-derived PPARα mRNA levels.
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Figure 21: Quantigene® analysis to determine siRNA knockdown of PPARα
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Figure 22: MCAD protein expression in SK-Mel 28 cells. Fifty µg whole cell lysate
was extracted from control and PPARα siRNA treated SK-Mel 28 cells at ~70%
confluence and subsequently separated by SDS-PAGE. The resulting blot was probed
using anti-MCAD (Cayman Chemical, Ann Arbor, MI) at 1:2000. Bands were visualized
using chemiluminescence detection. Equal loading was determined by Ponceau
staining.
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Figure 22: MCAD protein expression in SK-Mel 28 cells
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Figure 23 A and B: Images of SK-Mel 28 cells treated with control siRNA (A) or
PPARα siRNA (B). Ninety-six hour control siRNA (A) or PPARα siRNA(B) treatment.
Cell morphology was analyzed by visual analysis using images acquired by Olympus®
DX-184 microscope. Images are also representative of 48h siRNA experiment.
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Figure 23 A and B: Images of SK-Mel 28 cells treated with control siRNA (A) or
PPARα siRNA (B)

A

B
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DISCUSSION – Part I
PPARs have been implicated in a diverse range of biological processes. They
have been shown to activate many target genes that regulate a myriad of cellular
functions including cell cycle progression, differentiation, and apoptosis - all of which are
important to tumorigenesis. The first part of my dissertation tests the hypothesis that
the PPARs play a role in the development and/or progression of human melanoma.
Initially, I treated either normal human melanocytes, SK-Mel 28, or A375, vertical
growth phase and metastatic human melanoma cells respectively, with various PPARα
or PPARγ agonists to determine whether or not these could affect cellular growth, and
melanin production (Figures 4-16). I found that no PPARα agonist had any significant
effect on these human melanocytes and melanoma cells. Other studies have reported
similar results in human melanoma, concluding that the PPARα agonist WY-14643 had
no effect on the growth of A375 human metastatic melanoma cells (Nunez NP, Liu H
2005). My western blotting experiments show that PPARα is expressed in these cells.
However, it has been reported that PPARα may need to be phosphorylated to be fully
active in some cell lines (Juge – Aubry et al.,1999; Lazennec et al., 2000). It could be
that one of the kinases responsible for this phosphorylation is not fully active, or is not
present at sufficient levels in these cells. Another possibility is that a phosphatase is
overly targeting the activated PPARα resulting in a dephosphorylation, and thus
deactivation of this receptor in some sort of negative feedback scenario. Also, it is
possible that there are sufficient levels of active PPARα but it is saturated with an
endogenous ligand. Since the PPARα agonist also did not inhibit the growth of the
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normal human melanocytes, it is likely that PPARα activation does not lead to inhibition
of growth in melanocytes/melanoma cells.
Unlike PPARα, some PPARγ agonists were shown to have a significant effect on
cellular growth in the metastatic melanoma cells and the normal human melanocytes.
Expression and effect of ligand activation of PPARγ has been studied in human
melanoma. Both WM35, an early stage melanoma, and A375, a metastatic melanoma
cell line, have been reported to express PPARγ mRNA and protein. While one study
concluded that the growth of A375 cells was inhibited by ciglitazone (Placha et al.,
2003), another showed that the proliferation of A375 cells was unaffected by this
compound (Nunez et al., 2006). Ciglitazone had no effect on either SK-Mel 28 or A375
in these studies (Figures 6 and 10 respectively). PGJ2, a natural PPARγ agonist,
significantly inhibited A375 metastatic melanoma cell growth ~30% at 10µM compared
to DMSO treated cells (Figure 9). PGJ2 had no reproducible significant impact on
anchorage dependent growth or melanin production in the SK-Mel 28 vertical growth
phase (Figures 4 and 5 respectively) cells. PGJ2 had no reproducible significant effect
on the anchorage dependent growth in normal human melanocytes either (Figure 16).
Troglitazone, a potent synthetic PPARγ agonist, had a significant impact on cellular
growth in both the A375 cells (Figure 13) and the normal human melanocytes (Figure
14). At 10µM, TZD inhibited A375 cellular growth by ~55% compared to DMSO treated
cells. Normal human melanocytes showed a clear dose dependent response to TZD
with the 10µM treatment significantly inhibiting cellular growth by ~40% compared to
DMSO controls.
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Troglitazone had no reproducible significant impact on the SK-Mel 28 vertical
growth phase cells. Expression and effect of ligand activation of PPARγ has been
studied in human melanoma by others as well. While one study concluded that the
growth of A375 cells was inhibited by ciglitazone (Placha et al., 2003), another showed
that the proliferation of A375 cells was unaffected by this PPARγ agonist (Nunez et al.,
2006). It has been reported by others that PPARγ protein is expressed in WM35, an
early stage melanoma, and A375, the metastatic melanoma cell line (Placha et al.,
2003). My western blot analysis (Figure 20) shows that PPARγ is overexpressed in the
SK-Mel 28 cells relative to the normal human melanocytes, however it seems to not be
active in these cells. Neither PGJ2, TZD, nor ciglitazone had any significant affect on
these vertical growth phase cells. In contrast to PPARα, PPARγ phosphorylation results
in an inhibition of transcriptional activation of this receptor (Camp et al., 1999; Adams et
al., 1997). It is possible that there is a mutation in the PPARγ amino acid sequence at
either of the serines that are candidates for phosphorylation (Ser 82, 84, 110, or 112)
which results in a constitutively-inactive pseudophosphorylated conformation in these
cells. Another possible explanation is that the kinases responsible for the
phosphorylation of PPARγ are overexpressed or overly active in these cells resulting in
a hyperphosphorylated (thus inactive) PPARγ protein. Conversely, a phosphatase that
could be responsible for removing the phosphorylation from PPARγ could be inactivated
in these cells. Any of these changes, together with increased expression relative to
normal human melanocytes would result in a dominant-negative PPARγ in SK-mel 28
cells.
Next, I determined whether the human melanoma cells expressed the various
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PPAR subtype mRNAs. PPARδ and PPARγ1 and PPARγ2 are expressed in both SKMel 28 and A375 cells according to RT-PCR results (Figure 17). PPARα mRNA was
measured quantitatively using the Quantigene® assay system. Quantigene analysis of
the relative amounts of these PPAR subtypes was not performed, since no PPARγ
probes were available at the time of these experiments. PPARα mRNA was ~2 fold
higher in the SK-Mel 28 cells relative to both the normal human melanocytes and the
A375 metastatic cells (Figure 18). The PPARα mRNA level in the A375 was only a
negligible 0.14 fold higher than in the normal human melanocytes. This was not
consistent with the protein levels of PPARα, in these cells (discussed below). I
determined whether the various subtypes of PPARs are expressed at the protein level
in these cell lines. After numerous attempts, I found that both PPARα and PPARγ are
expressed in normal human melanocytes, vertical growth phase melanoma SK-Mel 28
cells, and metastatic melanoma A375 cells (Figures 19 and 20). PPARα protein was
highest in the A375 cells, being ~30% higher in these cells than in the SK-Mel 28 cells.
Normal human melanocytes, HEMn-LP, expressed the least amount of PPARα at ~60%
less than SK-Mel 28 and ~80% less than the A375 cells. This does not correlate with
the mRNA data from the same cell lines, where SK-Mel 28 cells had the highest levels
of PPARα mRNA, while A375 and HEMn-LP cells were nearly equal. This
inconsistency could be attributed to the fact that PPARα can be degraded via the
ubiquitin-proteasome pathway (Blanquart et al., 2002). It is possible that even though
the mRNA levels of PPARα are highest in the SK-Mel 28 cells, the PPARα protein in
these cells could be ubiquitinated at a higher rate relative to the A375 metastatic cells.
This would result in lower overall PPARα protein levels in the SK-Mel 28 cells compared
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to the A375 cells. PPARγ protein levels were consistently ~50% higher in the human
melanoma cells, SK-Mel 28 and A375, relative to the normal human melanocytes.
Lastly, I explored PPARα loss of function in the SK-Mel 28 vertical growth phase
cells. Since the mRNA levels of PPARα were highest in the SK-Mel 28 cells, I decided
to silence the expression of this gene using siRNA to determine how loss of PPARα
expression in these cells might affect their function. siRNA treatment from 48h up to
96h showed consistent knockdown of PPARα mRNA by ~80% in the SK-Mel 28 vertical
growth phase cells (Figure 21). Even though the knockdown was significant and
persistent, there was no observable biological effect in terms of morphology (Figures
23 A and B), nor was there any decrease in the expression of a PPARα target gene
MCAD (medium chain acyl-CoA dehydrogenase) (Figure 22). This lack of biological
effects could be due to the fact that there is redundancy of PPAR function between the
subtypes. In cells where PPARα is decreased the other PPARs, namely PPARγ, could
compensate for this loss. Another explanation is that 80% knockdown is not enough to
completely abolish PPARα function in these cells. However, the 80% knockdown of
PPARα results in an RNA level considerably below that found in normal human
melanocytes and therefore a reasonable conclusion is that the increased expression of
PPARα in SK-Mel28 melanoma cells is not contributing to its in vitro transformed
phenotypes.
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INTRODUCTION TO DISSERTATION PART II
The incidence of melanoma is increasing more rapidly than any other tumor type.
Melanoma accounts for 4% of all skin cancers, but for 79% of all skin cancer-related
deaths in the United States (Melanoma Research Foundation). It is notoriously
resistant to both chemo- and radiotherapy (Soengas and Lowe 2003). Melanoma cells
derive from the skin’s natural defense system to UV light, the melanocyte. Melanocytes
absorb UV light and in response, produce the pigment, melanin. To defeat the stresses
of this unique function, the melanocytes are inherently and naturally resistant to
apoptosis (Soengas and Lowe 2003). Understanding the molecular changes involved in
the progression of melanoma as well as the basis of its resistance to current therapies
is imperative to devising new strategies for its treatment.
One of the potential regulators of melanoma progression is the heterodimeric
transcriptional complex, HIF-1, also known as the master regulator of O2 homeostasis in
cells (Semenza G., 2003). HIF-1 controls over 60 genes involved in many aspects of
oncogenesis, including tumorigenesis (Kondo et al., 2005; Zhang et al., 2004). Several
markers of tumorigenesis have been shown to be altered by either the overexpression
or inhibition of HIF-1. Hypoxia-induced or exogenous overexpression of HIF-1α directly
increased in vitro invasion by the human colon adenocarcinoma cells, HCT116
(Krishnamachary et al., 2003). Pancreatic cancer cells, PCI-10, which were
overexpressing exogenous HIF-1α showed a significant increase in the frequency of
xenograft growth post injection (Akakura et al., 2001). Inhibition of HIF-1α activity by
106

overexpression of a dominant-negative form of HIF-1α in pancreatic cancer cells, PCI43, resulted in an increase in apoptotic cells and a decrease in their ability to form
tumors in SCID mice (Chen et al., 2003). Other genes controlled by HIF-1 include those
involved in apoptosis (Zhang et al., 2004; Greijer, A. 2004) and genetic instability
(Koshiji et al., 2005). HIF-1 has also been implicated in the progression of several
cancers including mammary gland, prostate, brain, and lung (Goda et al., 2003). HIF1α is the regulatory subunit of HIF-1. It is regulated at the protein level by both oxygendependent and independent pathways (Semenza G., 2002). Overexpression of HIF-1α
has been shown to increase the tumorigenic potency of renal cell carcinoma and
bladder cancer cells (Kondo et al., 2005). HIF-1α inhibition by siRNA in HCT116
(human colon cancer) cells resulted in no tumor growth compared to control cells when
introduced into nude mice (Zhang et al., 2004).
HIF-1α785 is a novel splice variant of HIF-1α that is characterized by excision of
exon 11 and splicing of exons 10 and 12 (Chun et al., 2003). While this splice variant
retains the remainder of the functional domains of HIF-1α, it loses lysine 532 in exon 11
that is usually acetylated by the acetyltransferase, ADP-ribosylation factor domain
protein 1 (ARD-1) (Jeong et al., 2002). This acetylation on lys 532 of HIF-1α is critical
for enhanced HIF-1α binding to the von Hippel Lindau (VHL) tumor suppressor protein,
which acts as an E3 ubiquitin ligase. VHL binding to HIF-1α brings about degradation
of HIF-1α by the proteasome. Since binding to VHL is a critical component of HIF-1α
degradation, HIF-1α785 is rendered more stable by lacking this lysine 532.
In addition to the stability, there are other characteristics that set the splice
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variant apart from full length HIF-1α. HIF-1α785 has been shown to be regulated by
different stimuli and pathways in comparison to HIF-1α. HIF-1α785 does not require
hypoxic conditions to be stabilized. Instead, HIF-1α785 can be stabilized by the phorbol
ester, PMA (Lim et al., 2004). HIF-1α785 has also been shown to be upregulated in
response to hyperthermia (42ºC) as well as by the Ras/Raf/MEK/ERK pathway (Lim et
al., 2004). In an in vivo nude mouse model, this splice variant was shown to render a
faster growing, larger, and more hypervascular tumor than HIF-1α (Chun et al., 2003).
Expression and role of HIF-1α785 in melanoma has yet to be elucidated.
The hypothesis was that inhibition of HIF-1α or HIF-1α785 would decrease
tumorgenicity in the human metastatic melanoma cells while overexpression of HIF-1α
or HIF-1α785 in radial growth phase cells would increase their tumorgenicity. In this
part of my thesis I found that this splice variant is expressed in human melanoma cell
lines while it is significantly lower in the normal human melanocytes. qPCR data shows
an increase in HIF-1α and especially HIF-1α785 mRNA as a function of malignant
progression, while remaining nearly undetectable in normal human melanocytes.
Overexpression of HIF-1α and HIF-1α785 resulted in increased anchorage independent
growth in the radial growth phase SbCl2 human melanoma cells, with HIF-1α785 having
a greater effect. Knockdown of HIF-1α by siRNA in the human metastatic melanoma
cell line, WM9, resulted in a ~50% decrease in matrigel invasion. Suppression of HIF1α also led to a ~50% - 60% decrease in anchorage independent growth in the WM9
cells. The gain of function data in SbCl2 radial growth phase human melanoma cells
indicates that the putative tumor promoter, HIF-1α785, is a potent effector of
tumorgenicity in these cells. These data show that the full length HIF-1α is able to
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increase soft agar colony formation, while the HIF-1α785 variant has an even greater
effect. The loss-of-function data for HIF-1α induced by siRNA, suggest that inhibition of
this transcription factor in metastatic human melanoma cells has a negative effect on
tumorgenicity.
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CHAPTER II

Function of HIF-1 in human melanoma progression
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MATERIALS AND METHODS

Cell lines and cell culture conditions
SbCl2 (RGP), WM1366 (VGP), and WM9 (Metastatic melanoma) cells were a
generous gift from Meenhard Herlyn’s lab at the Wistar Institute (University of
Pennsylvania). All cells were incubated in a humidified incubator with 5% CO2 and 95%
air at 37°C. The SbCl2 cells were cultured in MCDB153 media (Invitrogen, Carlsbad
CA), a powder brought up in autoclaved ddH20. Sodium bicarbonate (1.2g/L) was added
and the pH was adjusted to ~7.4 using NaOH. Approximately 400mL of the resulting
liquid MCDB153 media was supplemented with 10 mL fetal bovine serum, 800uL CaCl2,
250uL insulin (Sigma Chemical, St. Louis, MO), and 5mL penicillin/streptomycin solution
at 10,000 U/L (Invitrogen Corp., Carlsbad CA). WM1366 and WM9 cells were cultured
in RPMI medium (Invitrogen Corp., Carlsbad CA). RPMI (500 mL) was supplemented
with 10% fetal bovine serum and 5 mL penicillin streptomycin solution. Normal human
melanocyte (HEMn-LP) cell culture conditions were as described previously.

Western Blot analysis of HIF-1α
Nuclear extracts from each cell line were isolated using the NePER kit® (Pierce,
Rockford, IL) according to the manufacturer’s protocol when cells were no more than
~70% confluent. Protein concentration was determined using the BCA protein assay
reagents from Pierce as per the manufacturer’s instructions. Proteins were separated
by SDS-PAGE and transferred to nitrocellulose membranes using the BioRAD
MiniProtean3® system. Equal loading was also determined by Ponceau staining of the

111

nitrocellulose membranes. Blots were blocked using ChemiBlocker® reagent
(Chemicon, Temecula, CA) and probed overnight at 4°C with anti-HIF-1α monoclonal
antibody at 1ug/mL (R&D Systems, Minneapolis, MN). Monoclonal mouse secondary
IgG antibody (GE Healthcare, Piscataway, NJ) was applied after three 100 mL 1x TBS +
0.05% Tween (TBS-T) washes. Blots were incubated with secondary antibody at
1:3,000 for 1h at room temperature and subsequently washed 3x with100mL 1x TBS-T.
A final 5 minute wash with 100mL TBS (no Tween) was performed just prior to
incubating the blot with ECL reagent (GE Healthcare, Piscataway, NJ). Blots were then
autoradiographed.

RT-PCR for HIF-1α and HIF-1α785
RT-PCR was carried out as described previously. Primers were designed to
either amplify only HIF-1α or HIF-1α785 exclusively. HIF-1α primers would exclude
HIF-1α785 by targeting exon 11, which is absent in HIF-1α785. HIF-1α785 primers
were designed to exclude HIF-1α by targeting the exon 10:12 boundary only present in
HIF-1α785. The sequence of HIF-1α forward primer is 5’AAAGTTCACCTGAGCCTAAT-3’, and the sequence of the reverse primer is 5’TAAGAAAAAGCTCAGTTAAC-3’. The sequence of HIF-1α785 forward primers is 5’AAAGTTCACCTGAGGACAC-3’. The sequence of the HIF-1α785 reverse primer is 5’TAAGAAAAAGCTCAGTTAAC-3’.

Quantitative PCR for HIF-1α and HIF-1α785
Total RNA was extracted from HEMn-LP, SbCl2, WM1366, and WM9 cells at

112

both 24h (~40% confluent) and 72h (~70% confluent) after seeding using TRIZOL®
reagent according to the manufacturer’s protocol. RNA was then converted to cDNA
using the High Capacity cDNA Archive Kit (Applied Biosystems Inc. (ABI), Foster City,
CA). qPCR analysis was performed using TaqMan probes for HIF-1α (ABI Catalog
number Hs00936366) or HIF-1α785 (ABI Custom Primer Order) as well as β-actin (ABI
Catalog number 4326315E). The reactions were performed under conditions specified
in the ABI TaqMan Gene Quantitation assay protocol. Data was corrected for efficiency
and loading using the Pfaffl method (Pfaffl M., 2001). Data are representative of at least
3 separate experiments.

Overexpression of HIF-1α or HIF-1α785 in SbCl2 cells
The pLenti-V5-D-TOPO vector was used in gain of function experiments in the
SbCl2 radial growth phase human melanoma cells. I cloned either HIF-1α or HIF-1α785
into this vector by amplifying these genes by primers specific for both the 5’ and 3’ ends
of HIF-1α. The linearized pLenti-V5-D-TOPO Vector contains a GTGG overhang at one
end while the insert is Taq Amplified to contain a 5’-CACC overhang at one end.
Following amplification, 20µL of the 50µL PCR amplification reactions were separated
on a 1% agarose gel stained with ethidium bromide to ensure the correct size amplicon
was present. HIF-1α and HIF-1α785 amplicons were purified from the remainder of the
PCR reaction using the Zymo DNA Clean & Concentrate Kit® (Zymo Research Inc.,
Orange, CA). After ligation, plasmids were transformed into a premade OneShot® vial
of Stbl3® competent cells (Invitrogen Corp., Carlesbad, CA) and plated onto agar plates
containing 100ug/mL ampicillin. Plates were incubated at 37°C overnight and then
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colonies were screened for intact insert in the correct orientation. Plasmids were
isolated from positive colonies and analyzed by DNA sequencing to ensure the correct
plasmid expression construct. Control plasmid, pLenti-V5-LacZ, was supplied in the
ViraPower kit® (Invitrogen Corp., Carlsbad, CA).

siRNA inhibition of HIF-1α in WM9 human metastatic cells
WM9 cells seeded into 6 well plates at 5.0 x 104 cells per well were treated 24h
after seeding with either 100nM HIF-1α siRNA or 100nM control non-targeting siRNA
(Dharmacon, Inc. Lafayette, CO) using the RNAifect® transfection reagent (Qiagen,
Inc.) as per the manufacturer’s instructions. Briefly, siRNA oligos were diluted to a
stock concentration of 10mM using 1x siRNA buffer (Dharmacon, Inc. Lafayette, CO).
Final concentration of siRNA (100 nM) was obtained by diluting stock into the
appropriate amount of RNAifect® transfection reagent as per product manual. HIF-1α
down-regulation was confirmed by western blot at 48, 72, 96, and 120h after
transfection. There was ~60% - 70% decrease in HIF-1α protein relative to control
siRNA treated WM9 cells at each time point.

Matrigel invasion assay
WM9 cells treated with either 100nM HIF-1α siRNA or 100nM control nontargeting siRNA (Dharmacon, Inc.) for 24h were seeded into 6-well matrigel (+)
chambers, and, as a control, 6-well matrigel (-) chambers (BD Biosciences) at 7.0x104
cells per well. At 24 hours post-seeding, the matrigel was removed from the chambers
using a cotton-tipped applicator. After all the matrigel on the inner part of the chambers
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was removed, invading cells were fixed with 80% methanol for 5 minutes and then
stained with 0.5% crystal violet for 5 minutes. After staining, the cells/chambers were
extensively washed in dH2O. Once excess stain was removed, cells were manually
counted using a grid system covering the entire lower surface of the chamber. Results
are expressed as % HIF-1α siRNA treated-WM9 invasion relative to control siRNA
treated-WM9 invasion, both corrected for the invasion of similarly treated cells seeded
in matrigel (-) chambers.

Anchorage-independent growth assay
CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.) was used to
determine anchorage-independent growth of SbCl2 cells overexpressing either HIF-1α,
HIF-1α785, or LacZ. SbCl2 cells were transfected at ~80% confluence with either
pLenti-LacZ, pLenti-V5-D-TOPO-HIF-1α, or pLenti-V5-D-TOPO-HIF-1α785 using
FuGene 6 transfection reagent as per manufacturer’s protocol (Roche, Palo Alto, CA).
The next day 1.0x104 cells from each of the control (non-transfected), LacZ, HIF-1αFL,
or HIF-1α785 cells were seeded into a 0.4% agar layer poured over a 0.6% agar layer in
wells of a 96 well plate. Wells lacking cells served as a fluorescent blank control. Agar
layers were solubilized using a multichannel pipette, cells were lysed, and nucleic acid
content stained with 15µL CyQuant dye. The amount of Cyquant dye in each well was
determined using a fluorescent plate detector at 485/520 nm.
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RESULTS

Expression of HIF-1α in human melanoma cells
Here, we show for the first time in human melanoma, the oxygen-labile HIF-1α
protein is expressed endogenously with no external stimuli under normoxic conditions in
both metastatic cell lines A375 and WM9. Normoxic expression of HIF-1α is usually
inhibited due to the activity of the PHD and ARD1 proteins. These proteins target the
HIF-1α subunit for degradation via the ubiquitin-proteasome pathway. HIF-1α was
detected as a band ranging from ~114kD – 120kD in nuclear extracts from the
metastatic human melanoma cells.

Figures 24 A and B show that HIF-1α is clearly

overexpressed in the A375 and WM9 cells relative to normal human melanocyte
(HEMn-LP), radial growth phase (SbCl2), and vertical growth phase cells (WM1366).

Expression of HIF-1α mRNA
Regulation of HIF-1α at the RNA level, while very rarely mentioned in the
literature, could be significant in the progression of human melanoma. I determined
HIF-1α and HIF-1α785 mRNA levels initially by RT-PCR (Figure 25) and subsequently
by qPCR (Figure 26 A and B). Both Figures 25 and 26 show that in the cell lines
examined, the relative amounts of HIF-1α and HIF-1α785 mRNA increase as a function
of malignant progression, while remaining nearly undetectable in normal human
melanocytes. Primers were designed so that full length HIF-1α would exclude HIF1α785 by targeting exon 11, which is absent in HIF-1α785. Primers for HIF-1α785
excluded HIF-1α by targeting the exon 10:12 boundary only present in HIF-1α785. At
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24h there is an increase of ~9 fold for the HIF-1α full length mRNA over the HEMn-LP
levels while the HIF-1α785 mRNA levels rise ~8 fold over the HEMn-LP levels. At 72h
post seeding, the HIF-1α full length exhibited ~21 fold increase over the HEMn-LP
levels. HIF-1α785 mRNA levels showed ~78 fold increase in expression over the
HEMn-LP.

HIF-1α and HIF-1α785 gain of function in radial growth phase SbCl2 cells
The relative levels of HIF-1α protein are nearly undetectable in the early stage
radial growth phase SbCl2 cells. To test the hypothesis that overexpresson of HIF-1α in
a cell line that initially had very low levels could increase their tumorgenicity I used
these SbCl2 cells as a model for this overexpression. I wanted to determine the effects
that HIF-1α or HIF-1α785 overexpression would have on the malignant properties of
these cells. HIF-1α or HIF-1α785 was cloned into the pLenti-V5-D-TOPO vector,
represented in Figure 27. While cloning of the HIF-1α gene was very routine, the
successful cloning of the HIF-1α785 fragment with no rearrangements/mutations was
extremely difficult. Cloning into lentiviral vectors proves arduous since the long terminal
repeat sequences in the vectors are prime targets for e. coli-derived rearrangements.
After numerous attempts, a positive clone was identified. To be sure that there were no
rearrangements or mutations, DNA sequencing was performed in the Marshall
University DNA core facility and an experiment to determine whether or not the V5
epitope was cloned in frame was performed. Figure 28 shows that the HIF-1α785
variant was successfully cloned in frame and tagged with the V5 epitope. Figure 29
shows overexpression of HIF-1α or HIF-1α785 in SbCl2 cells leads to increased
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anchorage-independent growth, with HIF-1α785 having the greater impact. These
results do support the hypothesis that in a cell line initially void of HIF-1α or HIF-1α785
expression can exhibit increased tumorgenicity when these genes, especially the HIF1α785 are introduced.

HIF-1α loss-of-function in human metastatic melanoma WM9 cells
I have shown that HIF-1α protein is stabilized under normoxic conditions in both
human metastatic melanoma cell lines. HIF-1α could be affording these cells certain
survival advantages, therefore, the effects of HIF-1α inhibition was determined. To test
the hypothesis that lowering the levels of HIF-1α in a cell line could lessen the cells
tumorgenicity, WM9 cells were treated with siRNA targeting HIF-1α. The siRNA
treatment decreased the expression of HIF-1α by ~75-85% consistently. In the human
metastatic cell line, WM9, knock down of HIF-1α significantly inhibits both matrigel
invasion and anchorage-independent growth. Matrigel invasion was decreased in HIF1α-siRNA treated WM9 cells by 53% compared to control siRNA treated WM9 cells
(Figure 30). Anchorage-independent growth at day 4 was inhibited by 40% relative to
control siRNA-treated WM9 cells (Figure 31). Anchorage-independent growth was
inhibited by 70% at day 5 compared to control siRNA-treated WM9 cells (Figure 32).
These results support the suggestion that lowering availability of the HIF-1α in the WM9
cells decreases their tumorgenicity.
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Figure 24 A and B: HIF-1α protein expression in A375 and HEMn-LP (A) and
HEMn-LP, SbCl2, WM1366, and WM9 (B). A. Sixty µg of cytoplasmic and nuclear
extracts from ~70% confluent A375 and normal human melanocytes were separated via
SDS-PAGE and probed with monoclonal anti-HIF-1α (1ug/mL) at 1:10,000. Equal
loading was determined by Ponceau staining. This blot is representative of at least 4
separate experiments. B. Sixty µg of nuclear extracts from HEMn-LP (normal human
melanocytes), SbCl2 (radial growth phase melanoma), WM1366 (vertical growth phase
melanoma), and WM9 (metastatic melanoma) were separated via SDS-PAGE and
probed with monoclonal anti-HIF-1α (1ug/mL) at 1:10,000. Equal loading was
determined by Ponceau staining. This blot is representative of at least 4 separate
experiments. M = molecular weight marker.
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Figure 24: HIF-1α protein expression in A375 and HEMn-LP (A) and HEMn-LP,
SbCl2, WM1366, and WM9 (B)

A.

B.
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Figure 25: RT-PCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366, and
WM9. Total RNA was extracted from normal human melanocytes (HEMn-LP), radial
growth phase (SbCl2), vertical growth phase (WM1366), and metastatic melanoma cells
(WM9). RNA integrity was determined using the Agilent Bioanalyzer®. RNA was
reverse transcribed using the Advantage RT-for PCR kit®. 5uL of the resulting cDNA
was used in the PCR reaction as described in the Advantage cDNA kit® manual.
Primers for HIF-1α and HIF-1α785 were designed to specifically amplify each variant
with no cross-amplification. Primers for the housekeeping gene control GAPDH were
included in the Advantage cDNA kit®. Control primers amplifying a fragment of the
control plasmid included in the Advantage cDNA kit® were used to ensure optimal PCR
conditions. M = molecular weight marker.
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Figure 25: RT-PCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366, and
WM9
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Figure 26 A and B: qPCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366,
and WM9 at 24h (A) or 72h (B). Total RNA was extracted from HEMn-LP, SbCl2,
WM1366, and WM9 cells at both 24 (A) and 72h (B). RNA was then converted to cDNA
using the High Capacity cDNA Archive Kit (ABI). qPCR analysis was performed using
TaqMan probes directed at HIF-1α or HIF-1α785 as well as β -actin. The reactions
were performed under conditions specified in the ABI TaqMan Gene Quantitation assay
protocol. Data was corrected for efficiency and loading using the Pfaffl method. Data is
presented as fold change corrected for β-actin relative to HEMn-LP. Data is
representative of at least 3 separate experiments.

123

Figure 26 A and B: qPCR for HIF-1α and HIF-1α785 in HEMn-LP, SbCl2, WM1366,
and WM9 at 24h (A) or 72h (B)
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Figure 27: Representation of the pLenti-V5-D-TOPO vector. Representation of the
pLenti-V5-D-TOPO vector (taken from Invitrogen Corp.) used in gain of function
experiments in the SbCl2 radial growth phase human melanoma cells. Both full length
genes for HIF-1α and HIF-1α785 were amplified by primers specific for HIF-1α. A
linearized D-TOPO Vector contains a GTGG overhang at one end while the insert is
Taq Amplified containing a 5’ -CACC overhang at one end. Expression results in the
protein of interest tagged with the V5 epitope. The V5 epitope tag is derived from a
small epitope (Pk) present on the P and V proteins of the paramyxovirus of simian virus
5. It usually consists of either all 14 amino acids (GKPIPNPLLGLDST) or sometimes a
shorter version consisting of only 9 amino acids (IPNPLLGLD).
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Figure 27: Representation of the pLenti-V5-D-TOPO vector taken from Invitrogen
Corp.
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Figure 28: Expression of HIF-1α785 tagged with the V5 epitope in SbCl2 cells.
SbCl2 cells were transiently transfected with pLenti-D-TOPO-HIF-1α785. At 48h post
transfection, cells were lysed and whole cell lysate was extracted and separated by
SDS-PAGE. After transfer and blocking with Chemi-Blocker®, HRP-conjugated Anti-V5
antibody was incubated with the membrane for 1h. After extensive washing and a 5
minute incubation with ECL® reagent, bands were visualized using autoradiography.
Molecular weight marker, MagicMark XP® (M), was used to confirm correct kD size for
the expected expression product (~87kD).
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Figure 28: Expression of HIF-1α785 tagged with the V5 epitope in SbCl2 cells.
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Figure 29: Anchorage-independent growth of SbCl2 cells expressing HIF-1α or
HIF-1α785. CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.): SbCl2
cells were transfected at 80% confluence with either pLenti-LacZ, pLenti-V5-D-TOPOHIF-1aFL, or pLenti-V5-D-TOPO-HIF-1α785 using FuGene 6 transfection reagent. The
next day 1.0x104 of each of the control (non-transfected), LacZ, HIF-1aFL, or HIF-1a785 cells were seeded into a 0.4% agar layer poured over a 0.6% agar layer in wells of
a 96 well plate. Wells lacking cells served as a blank control. Agar layers were
solubilized, cells were lysed, and nucleic acid stained with CyQuant dye. The intensity
of fluorescence in the well was determined by a fluorescent plate reader at 485/520 nm.
Data is shown as relative light units of CyQuant® fluorescence. Figure is representative
of at least 3 experiments.
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Figure 29: Anchorage-independent growth of SbCl2 cells expressing HIF1α or HIF-1α785
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Figure 30: Matrigel invasion assay in WM9 cells treated with HIF-1α siRNA. WM9
cells were treated with either 100nM HIF-1α siRNA or 100nM control #1 non-targeting
siRNA (Dharmacon, Inc.) using the RNAifect® transfection reagent (Qiagen, Inc.). At
24h post transfection, the cells were seeded into 6-well matrigel (+) chambers, and as a
control, 6-well matrigel (-) chambers (BD Biosciences) at 7.0x104 cells per well. At 24
hours after seeding, the matrigel was removed from the matrigel (+) chambers using a
cotton-tipped applicator. After all matrigel on the inner part of the chambers was
removed, invading cells were fixed with 80% methanol for 5 minutes and then stained
with 0.5% crystal violet for 5 minutes. After staining, the cells/chambers were
extensively washed in enough dH2O to remove excess stain. Once excess stain was
removed, cells were manually counted using a grid system covering the entire lower
surface of the chamber. The number of invaded cells treated with HIF-1α siRNA
relative to the number of invaded cells treated with control siRNA was determined. Both
were corrected for the number of similarly-treated invading cells seeded in matrigel (-)
chambers. Results are expressed as cell number as % control. Experiment was done
in triplicate and repeated at least 3 times. Error bars represent standard error. *
denotes p = 0.0022.
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Figure 30: Matrigel invasion assay in WM9 cells treated with HIF-1α siRNA
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Figure 31: Anchorage independent growth of WM9 cells treated with HIF-1α
siRNA – Day 4. WM9 cells were treated with either 100nM HIF-1α siRNA or 100nM
control #1 non-targeting siRNA (Dharmacon, Inc.) using the RNAifect® transfection
reagent (Qiagen, Inc.). At 24h post transfection, anchorage independent growth was
analyzed using the CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.).
Briefly, the cells were seeded at 8.0x103 cells/well into a 0.4% agar layer poured over a
0.6% agar layer in wells of 96 well plate. Wells lacking cells served as a blank control.
On day 4 after seeding, agar layers were solubilized, cells were lysed, and nucleic acid
stained with CyQuant® dye. Intensity of the fluorescence in each well was determined
by a fluorescent plate reader at 485/520 nm. Results are expressed in Relative
Fluorescent Units. Experiment was done in triplicate and repeated at least 3 times.
Error bars represent standard error. * denotes p = 0.032
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Figure 31: Anchorage independent growth of WM9 cells treated with HIF-1α
siRNA – Day 4
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Figure 32: Anchorage independent growth of WM9 cells treated with HIF-1α
siRNA – Day 5. WM9 cells were treated with either 100nM HIF-1α siRNA or 100nM
control #1 non-targeting siRNA (Dharmacon, Inc.) using the RNAifect® transfection
reagent (Qiagen, Inc.). At 24h post transfection, anchorage independent growth was
analyzed using the CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.).
Briefly, the cells were seeded at 8.0x103 cells/well into a 0.4% agar layer poured over a
0.6% agar layer in wells of a 96 well plate. Wells lacking cells served as a blank control.
On day 5 after seeding, agar layers were solubilized, cells were lysed, and nucleic acid
stained with CyQuant® dye. Fluorescence intensity in each well was determined by a
plate reader at 485/520 nm. Results are expressed in Relative Flourescent Units.
Figure is representative of at least 3 independent assays each done in triplicate. Error
bars represent standard error. * denotes p = 0.0016
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Figure 32: Anchorage independent growth of WM9 cells treated with HIF-1α
siRNA – Day 5
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DISCUSSION – Part II
For the second half of my dissertation work, I wanted to determine the role of the
hypoxia inducible factor -1α (HIF-1α) and its splice variant, HIF-1α785 in human
melanoma progression. These results indicate that HIF-1α and its variant likely play
important roles in the progression of this disease.
Melanocytes, the cells responsible for producing the skin-coloring pigment,
melanin, are the point of origin for melanoma. Melanoma, if diagnosed and treated
early, has a very high cure rate. If the melanoma progresses, it can metastasize
(becoming metastatic melanoma) to the lymph nodes, lungs, and the brain. Metastatic
melanoma is very difficult to treat and has a much higher mortality rate than primary
melanoma. Several studies have confirmed that HIF-1α is very often a survival factor in
various cancers, however this has not been shown in human melanoma.
I found that HIF-1α protein is expressed under normoxic conditions at higher
levels in human metastatic melanoma cells (A375 and WM9) than in the normal human
melanocytes (HEMn-LP), radial growth phase melanoma (SbCl2), and vertical growth
phase melanoma (WM1366) cells (Figure 24 A and B) . The fact that it is detectible in
the metastatic cells is novel, since it is very quickly degraded under normoxic conditions
in the majority of all cell lines tested to date.
More importantly, I have shown that both the full length HIF-1α as well as its
splice variant, HIF-1α785, show increasing levels of mRNA expression as a function of
malignant progression (Figure 26 A and B). Once corrected for both a housekeeping
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gene and for primer/probe binding efficiency, the metastatic melanoma cells, WM9,
showed ~10 fold increase in both HIF-1α and HIF-1α785 mRNA levels relative to the
normal human melanocytes at 24h after seeding and ~21 fold increase over normal
human melanocytes at 72h after seeding in the HIF-1α. There was nearly a 78 fold
increase in the expression of HIF-1α785 in the metastatic melanoma cells over the
normal human melanocytes at the 72h time point. These time points are significant
since in the literature there are hints that “crowding” of the cells in culture dishes can
influence HIF-1α protein levels. At 24h after seeding there was around 30% confluence,
while at 72h there was ~70% confluence. All protein isolations were done at 48h postseeding, therefore it can reasonably be concluded that this “crowding” effect should not
have been a confounding variable in my western blot data. While there is some chance
that these results could be due to the cells being exposed to different culture conditions,
there is currently no way to correct for this situation. However, it does seem reasonable
that if the normal human melanocytes need a certain microenvironment to flourish in
vivo and the RGPs need an even more altered microenvironment in vivo, and so on for
the other phases of human melanoma represented here, that these different culture
conditions in vitro are valid for comparison.
There is very little information from any cell line on regulation of HIF-1α or its
variant at the RNA level. Thus my findings are significant since they indicate a novel
control point for HIF-1 activity in human melanoma, as well as in other cell lines. This
RNA regulation could be due to transcription factors responsible for HIF-1α/HIF-1α785
gene expression becoming overexpressed or over-active as a function of melanoma
progression. However, since I have not shown that the increase in HIF-1α mRNA is due
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to increased transcription, there remains the formal possibility that post-transcriptional
regulation, such as increased mRNA stability could contribute to the increase I observed
in the melanoma cells. This overexpression of HIF-1α and thus availability of the active
HIF-1 heterodimer, would give these cells a survival advantage. One survival
advantage that HIF-1 overexpression could lend to the metastatic cells is their ability to
invade and metastasize since HIF-1 is a transcriptional regulator of many genes
involved in these processes, such as matrix metalloproteinases (MMPs).
The SbCl2 radial growth phase melanoma cells showed negligible levels of HIF1α protein expression and were therefore chosen to determine the effects of HIF-1 gain
of function. I have shown that the human melanoma radial growth phase cell line,
SbCl2, which has very limited anchorage independent growth capabilities, has an
increased ability to grow in soft agar when overexpressing full length HIF-1α.
Overexpression of the HIF-1α785 splice variant resulted in the greatest increase in soft
agar colony formation relative to control cells (Figure 29). One possibility for the
increased anchorage independent growth exhibited in the splice variant HIF-1α785overexpressing cell line is the splice variant protein having a longer half-life compared to
the full length HIF-1α. The longer half life for HIF-1α785 is presumed since it is missing
a critical Lys532 that is acetylated by ARD1. This acetylation enhances HIF-1α
interaction with the von Hipple Lindau tumor suppressor protein which acts as an E3
ubiquitin ligase. Without this acetylation, HIF-1α could have a less favorable interaction
with this protein, therefore increasing the chances it will not be degraded by the
ubiquitin-proteosomal system. HIF-1α785 has the same function as HIF-1α; therefore
longer half life could ultimately lead to more active heterodimeric HIF-1 available for
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cellular processes. Future studies need to be done to determine the relative half-life of
both the full length and splice variant using traditional methods.
HIF-1α loss of function experiments were carried out in the WM9 metastatic
melanoma cell line. This cell line was chosen due to its high levels of HIF-1α
expression. Silencing of HIF-1α by siRNA treatment resulted in a significant decrease
(52%) in matrigel invasion compared to WM9 cells treated with control siRNA (Figure
30). One possibility of these results is that HIF-1 has been shown to control the
expression of several genes involved in invasion such as matrix metalloproteinase 2
(MMP2), urokinase plasminogen activator receptor (uPAR), and cathepsin D
(Krishnamachary et. al., 2003; Luo et. al., 2006).
HIF-1α loss of function also resulted in a significant decrease in anchorageindependent growth in the metastatic melanoma cells. Silencing of WM9 cell HIF-1α by
siRNA resulted in ~40% decrease in their ability to form colonies in soft agar at 4 days
of treatment (Figure 31). After 5 days of treatment, there was ~68% decrease in
anchorage-independent growth in the HIF-1α silenced WM9 cells relative to the control
siRNA treated cells (Figure 32). Anchorage-independent growth is a hallmark of cancer
cells. The WM9 cells were shown to have a marked increase in the endogenous
amount of HIF-1α protein according to western blotting (Figure 24 A and B).
Anchorage-independent growth could be decreased in the WM9 cells treated with HIF1α siRNA due to PI3K/Akt and HIF-1 pathway interactions. The PI3K/Akt pathway is
one of the most critical pathways involved in anchorage-independent growth (Wang L.,
2004). Anoikis, or cellular death due to loss of interaction with the extracellular matrix
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and subsequent initiation of caspase-mediated apoptosis, is increased in these cells
when HIF-1α levels are depleted by the siRNA treatment. PI3K/Akt has been shown to
control HIF-1 activity by increasing the translation of the HIF-1α protein (Treins et. al.,
2002). If PI3K/Akt regulates anchorage-independent growth through this increased HIF1 activity, the silencing of HIF-1α could lead to a decrease in anchorage-independent
growth.
The normoxic regulation of HIF-1 has only recently been explored. Studies are
needed to determine the role that elevated HIF-1α levels under normoxic conditions
may play in the progression of cancers. One future goal of our laboratory is to
determine whether or not there are different gene sets activated by normoxic HIF-1
relative to hypoxic HIF-1. Other future studies could include using the recombinant
lentiviral particles that I have generated to introduce both full length and the splice
variant of HIF-1α into normal human melanocytes to determine their effects on
malignant transformation.
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SUMMARY AND CONCLUSIONS
The first part of my dissertation work dealt with the expression and possible
function that PPARs play in human melanocytes compared to human melanoma cells.
These studies revealed that none of the human melanoma cells tested were
significantly or reproducibly affected by PPARα agonists, but the normal human
melanocytes and metastatic melanoma cells, A375 were significantly growth inhibited
by PPARγ agonists. While PPARα and PPARγ protein levels are overexpressed
relative to the normal human melanocytes, only the SK-Mel 28 cells exhibited a
significant increase in PPARα mRNA levels. When PPARα expression was silenced in
SK-Mel 28 cells utilizing siRNA, no observable biological effect was seen in these cells
compared to cells treated with control siRNA. A reasonable conclusion is that the
increased expression of PPARα in SK-Mel 28 cells is not contributing to its in vitro
transformed phenotype.
The second part of my dissertation work focuses on the expression and role HIF1α, under normoxic conditions in human melanoma progression. These results
revealed, for the first time, that HIF-1α is overexpressed in the metastatic melanoma
cells. Also, I have shown, for the first time, that there is regulation of HIF-1α at the
transcriptional level in human melanoma. The expression of both HIF-1α and HIF1α785 increases as a function of melanoma progression. Gain-of-function studies in the
HIF-1α-negative SbCl2 cells reveal that introduction of exogenous HIF-1α, or its splice
variant, can significantly increase their anchorage-independent growth. Loss-of-function
studies in the HIF-1α positive WM9 metastatic melanoma cells show that there is a
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significant decrease in matrigel invasion compared to control siRNA treated cells. The
loss of HIF-1α in these cells also significantly diminished their ability to form colonies in
soft agar. These results suggest that development of new therapeutic agents that
inhibit HIF-1 function may be of use in the treatment of human melanoma.
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